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ABSTRACT

A series of novel purine-based fluoroaryl triazoles were synthesized and assayed
for their neuroprotective effects of hippocampal slice culture exposed to amyloid beta
(A~)

oligomers. A monofluorinated triazole has been identified which has comparable

neuroprotective effect as that of flavopiridol and roscovitine against the

A~

induced

neurotoxicity.
Carnosine and histidine are biologically interesting antioxidants. In order to probe
whether they exe11 their antioxidant effect through metal ion chelation, the Cu(ll) ion
chelating abilities of these compounds were measured by UV-vis spectroscopy.
Amyloid beta, the major component of senile plaques in Alzheimer's disease, is
known to complex transition metal ions through histidine residues. In this study, using 1H
NMR titration experiments, it was shown that histidine binds strongly to Zn(II), Cu(Il),
and Fe(III) ions at a biologically relevant pH (pH 7.4), with a stoichiometry of Zn(II):
histidine binding of I :2.
Fluorinated

boroxines,

tris(2,6-difluorophenyl)boroxin

(DF),

tris(2,4,6-

trifluorophenyl)boroxin (TF), and tris(pentafluorophenyl)boroxin (PF) were synthesized
and investigated for their fluoride anion binding affinity using multinuclear Nuclear
magnetic resonance (NMR) and tandem mass spectroscopic techniques. DFT calculations
show that the fluoride ion complex of DF prefers unsymmetrical, covalently bound
structure over the symmetrically bridged species by 12.5 kcal/mol.
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1. PURINE-BASED FLUOROARYL-1,2,3-TRIAZOLES:
A~ OLIGOMERS AND CELL CYCLE PROTEIN INHIBITORS IN
ALZHEIMER'S DISEASE

1.1 CELL CYCLE INHIBITORS IN ALZHEIMER'S DISEASE

Amyloid beta plaques

(A~),

Neurofibrillary tangles (NFTs), neuronal loss and

dysfunction are the major pathological hallmarks of Alzheimer's disease (AD).
plaques consists of mainly A~ which derives from

A~

A~

precursor protein(APP).

Neurofibrillary tangles are made up of hyperphosphorylated forms of the microtubule
associated protein tau. Neuronal loss results in cognitive impairment in
neurodegenerative disease. Several hypotheses, such as the

A~

hypothesis and oxidative

stress, have been proposed to explain the contributing aspect of Alzheimer's disease
(AD). In recent years the concept of abnormal neuronal cell cycle re-entry is gaining
increasing attention, as a major causative factor for AD.1 1-21 AD brain is characterized by
over expression of cell cycle regulating proteins, 131 indicating that neuronal cells are
reentering the cell cycle leading to neuronal cell death.
Cell cycle is the cellular process, leading to proliferation and differentiation of
cells. The cell cycle is regulated by a group of protein kinase called cyclindependent
kinase (Figure 1.1 ). The four main phases of the cell cycle are, S phase where the DNA
replication take place, M phase where cell division happens and G 1 phase where cells
increase in size and get ready for DNA replication, G2 phase, the gap between DNA
replication and mitosis. When a cell is in any phase of the cell cycle other than mitosis, it
is often said to be in interphase. Cells that have temporarily or reversibly stopped
dividing are in a state of quiescence called Go phase. The neuronal cells in adult
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hippocampus are an example of quiescent cells. Such terminally differentiated cells are
generally incapable of reentering in to the cell cycle. They will continue their function in
GO phase. Under physiological conditions neurons are subjected to a variety of stimu li
and signals. They include mitogenic signals that promote reentry in to the cell cycle and
antimitogenic factors which strive to maintain the neurons in the GO phase. However,
conditions such as brain injuries can alter the balance, leading to cell cycle entry. It has
been shown that cell cycle proteins are over expressed in AD patients with mild cognitive
impairments. These are over expressed even before the appearance of A~ plaques
indicating that cell cycle reentry happens at the early stage of disease.
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Figure 1.1 Cell cycle proteins and CDKs which are involved in the different phases of
the cell cycle.
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1.1.1

Cell Cycle and Cyclindcpendent Kinases. Each phase of the cell cycle

is regulated by a group of cell cycle proteins and cyclin dependent kinases (CDKs)
(Figure 1.1 ). They are a group of serine/tlu·eonine kinases that are regulated by subunits
cyclins. Several CDKs are involved in the process of cell cycle. Mainly CDK4, CDK6,
CDKI and CDK2 cooperate to drive cells through the cell cycle by binding to appropriate
cyclins along with other cell cycle proteins (e.g. PCNA). Reentry of cells in the GO
phase to the G I phase are activated by CyclinD/CDK4/ PCNA(proliferating cell nuclear
antigen) complexes. [4 lCyclin E/CDK2 complexes are involved in the transition of G I
phase into S phase. cyclin A binds to CDKI in G2 and, together with CDKI-cyclin B,
lead to an entry into mitosis. Cell cycle progression from the G2 phase into Mitotic
phase is controlled by the presence or absence of Cyclin A Absence of Cyclin A may
lead to redifferentiation of the cells by returning to the GO phase. [S- 6!

1.1.2

CDK5 and Neurodegeneration. CDK5 is essential for both neuronal

differentiation and cell cycle inhibitionPl CDK5 is not directly involved in cell cycle
regulation. CDK5 activity increases, when neurons exit the cell cycle during the
differentiation. Loss of CDK5 leads to both failure of neuronal differentiation and loss of
cell cycle control. [S-IOJ CDK5 is present in all cell types, but its activity has been detected
only in the central nervous system (CNS). The cellular activity of CDK5 is regulated
naturally by other kinases, phosphates and inhibitory peptides. Binding of CDK5 to
cyclin-like p35, a neuron specific protein, leads to activation of the kinase. Normal
functions of CDK5/p35 include neurite outgrowth/ differentiation, regulation of
dopamine signaling through phosphorylation ofDARPP-32 and regulation of presynaptic
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neurotransmitter release.l''- 141 Over activated CDKS is able to phosph01ylate tau protein
leading to the formation of neurofibrillary tangles which is the main morphological
features of Alzheimer's brain. Membrane-bound p35, when activated by molecules like
amyloid~

converts into CDK5/p25 and relocalizes in to cytoplasm leading to

neurotoxicity. Its expression in the CNS is converse to the expression levels of the cell
cycle kinases. As neurons differentiate, CDK2 and CDK I are downregulated, while
CDKS expression increases. 1151 There are excellent reviews on role of CDKS in
neurodegenrationY 6 -18 l CDKS shares a high degree of homology with CDKI and CDK2
and selective inhibition is highly impotiant in therapeutic treatment.CDKS activity is
increased following axon injury and regeneration 1' 91 and treatment with roscovitine (2)
and olomoucine (3) reduces the extent of regeneration.

1.1.3

A~

Oligomers and Cell Cycle Reentry. It has been shown that although

cell cycle proteins are over expressed, this factor alone doesn't cause cell cycle reentry. It
needs stimuli from the molecules like

A~,

reactive oxygen species, nitric oxide and

others. Elevated levels of these molecules induce mitogenic signal cascades and when
this exceeds beyond a threshold neurons exit the GO state and reenter the cell cycle
(Figure 1.2).

A~

oligomers are more toxic than

A~

plaques, which are present around the

dying neurons. There are many theories on how A~ can be neurotoxic. A recent study
using transgenic mice show that (R 1.40 Tg) neurons reenter in to cell cycle, even 6
months before the appearance of A~ plaques.1201 Experiments in transgenic mice which
lack BACE show that the cell cycle proteins are not expressed. BACE is a protein that is
necessary for the production of A~ from its precursor. These results indicating that cell

5
cycle reentry happens at early stages of AD. The formation of A~ plaques occurs in the
later stage. When neurons, in vitro are subjected to

A~

oligomers, but not monomers,

there is increase in DNA synthesis, giving further evidence for the importance of A~
oligomers on cell cycle reentry.

The neuronal cells that reenter the cycle undergo

apoptosis before reaching the Mitotic stage. Evidences show that A~ induced neurons
proceed to the S phase and replicate DNA. Thus the neurons entering the cell cycle are
trapped in or before the s phase. They neither finish dividing nor enter in to the GO phase .

.
Ap! Oxidative stress

Figure 1.2.

1.1.4

A~

induced neurons proceed to S phase and replicate DNA.

AP and CDKS.

AP plaques occur around the neuron, when the balance of

AP generation and clearance is altered. Aberrant activation of kinases and inhibition of
phosphatases results in elevates the levels of AP and Neurofibrillary tangles.
Overactivation of CDK5, mediated by A

p results in tau-hyperphosphorylation, decreased
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levels of synaptic markers, and cell cycle reactivation leading to substantial neuronal
loss. 121 -221 In turn CDKS, in association with aberrantly formed protein p25 (by cleavage
of p35), is responsible for Neurodegeneration. P25 accumulation may precede the
formation ofNFT in AD brain. Even though the involvement of the p25 in the
intracellular neurofibrillary tangle (NFT) formation is not well established, 1231its role in
neuronal cell-cycle re-entry and resultant neuronal cell death is widely established. [24 ' 251
AP induces the cleavage p35-p25 in primary cortical neurons. 1261 Accumulation ofp25
and overactivation of CDKS resulted in elevated levels of AP-42 in APP transgenic
mice. 127 -281Inhibition of CDKS activity inhibits the AP induced neuronal cell death,
indicating that aberration in CDKS activity and formation of AP plaques are related to
each other. 1291 There are conflicting reports on the role of CDKS on APP processing.
CDKS inhibitors injected in to the transgenic mouse brain increased the level of AP in the
brain1301 and inhibition ofCDK5 in APP transfected HEK293 cells elevated the AP
secretion.

1.1.5
Cell Cycle Proteins and Cyclin Dependent Kinascs as Targets fot· the
Treatment of AD. Terminally differentiated neuronal cells are not capable of
proliferating by entering in to mitotc stage, where tumor cells entering the cell cycle are
capable of proliferating. Pathological evidence of AD shows the entry of neurons in GO
phase toG I phase or beyondY 1-331 Neurons undergo cell cycle progression in AD, to the
point that DNA replication occurs. 134 ' 351 AD neuron exhibits over expression of cyclins,
CDKs and other cell cycle regulating factors (e.g. PCNA). 131

131 321
-

Since cell cycle

reentry leads to neuronal death in neurodegenerative disease and cell proliferation in
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cancer, cell cycle inhibition prevents neuronal cells from dying as well as proliferation of
tumor cells. Thus cell cycle inhibition is a therapeutic strategy for both neurodegenerative
disease and cancer. [361 Several molecules are involved in cell apoptosis and
Neurodegeneration. l37 l A number of chemical inhibitors of neuronal apoptosis targeting a
variety of different proapoptotic proteins, including c-jun N-terminal kinase (JNK),
glycogen synthase kinases (GSK3), and p53 were investigated.l371 The main focus of this
review is inhibitors of cyclin dependent kinases.
Two distinct CDK pathways may have a role in the neuronal loss responsible for
AD. One pathway involves aberrant reactivation of the cell cycle, whereas a second
involves dysregulation ofCDK5.lJSJ Cell cycle inhibition by inhibiting CDKs was first
used in cancer therapy. The concept of inhibition of cell cycle reentry in
neurodegenerative disease got attention in recent years. Thus there are not many drug
discovery programs in this area targeting AD. Structurally diverse compounds including
indole,l39.421 imidazole,l4J.44l pyrazolopyridine, l45 l pyridopyrimidines, [461 piperidine,l 471
and purinel48 . 55 l derivatives have been tested as CDK inhibitors. l56 ' 57 l But not many of
these were tested for CNS disorder. Although many CDK inhibitors are under clinical
trial for tumor, no clinical trials of CDK inhibitors are reported for CNS disorder.
The class of CDK inhibitors which are reported for neurodegenerative diseases
include the nonselective CDK inhibitor, flavopiridol(l ); selective inhibitors of CDKl, 2,
and 5 such as roscovitine(2), olocomucine(3), and butyrolactone l (4); the selective
inhibitor ofCDK5, GW8510 (5),l 58 -59 l selective inhibitor ofCDK5 and CDK2,
Quinazolines(6),f60 ' 611 4.aminoimidazole(7), [621 indurubins (8), l63 l 6-oxo-l ,6dihydropyridines(9). [641 So far there is not a single CDK inhibitor which is selective for a
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pmticular CDK or other protein kinases. Most of them collectively inhibit either a group
of CDKs or other protein kinases.
Several CDK inhibitors have been developed over the past decade (Figure 1.3).
The first CDK inhibitor to reach clinical trial is Falvopiridol (1). Flavopiridol (I)
Roscovitine (2), olomoucine (3) are the most widely studied CDK inhibitors.l65 "661
Flavopiridol (I) is a broad spectrum CDK inhibitor where are purine derivatives are more
specific. The neuroprotective effect offlavopiridol (I) was suggested to be due to its
inhibition of CDK5 and to some extent CDK2. 1671 However, flavopiridol (I) also inhibits
other kinases, at higher concentrations. Additionally, disruption of RNA polymerase ITmediated transcription by flavopiridol (I) has been reported. 1681 Flavopiridol (I) may have
also role in inhibition of gene expression 1691 . Recent evidences show that l.methyl4.phenylpyridinium (MPP) induced neuronal cells undergo cell cycle reentry in to S
phase of the cell cycle. But in the presence offlavopiridol (I) and Olomoucine (3) the
neuronal cell cycle re-entry and apoptosis were attenuated. 167 • 701 Flavopiridol (I) and
Roscovitine (2) were also reported to be neuroprotectors in colchicines-induced cell
apotosis. 171 ] In vitro studies using HIV neurotoxicity model show that roscovitine (2) act
as a neuroprotector by inhibiting CDK5 activity. 1721 In a model of focal ischemia, (S)roscovitine (2) was able to cross the blood brain barrier and prevent Cerebral increase of
CDK5/p25 activity protecting the neurons in vivo. 173 1
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Figure 1.3. CDKs inhibitors which are currently under preclinical trial for treatment of
AD.I63J

Butyrolactone-I (4) is a selective inhibitor of cyclin dependent kinases,
particularly CDK5. [? 41Butyrolactone-1 (4) displays a selectivity profile similar to the
purine analogues (e.g. inhibits CDKs l, 2, and 5), and inhibits CDK 5 with an in vitro
IC50 of0.49!1M. Butyrolactone I(4) prevent memory consolidation by decreasing
baseline CDK5 activity within the septa-hippocampal circuitry.l7 51 The neurotoxic effect
of AP on primary cultures of hippocampal cells decreased on co-incubation of the
butyrolactone I.l291

10

A number of other 3.substituted indolones have also been found to inhibit
neuronal dcath. 159• 76 l GW5074 is a 3.substituted indolone (Figure 1-4), completely
inhibits the death of cultured neurons induced by a variety of different apoptotic
stimuli,1761 but it doesn't have any effect on any of the CDKs. Structurally similar
compound GW8510 (5) (Figure 1.3) inhibits CDKs in vitro but has a weak effect on
classical CDKs in cultured cells. GW8510(5) was discovered to be a potent inhibitor of
CDK2 (IC50

=

60 nM) when tested in vitro. [nJ In addition to CDK2, Davis and co-

workers reported that GW851 0 also inhibited other CDKs, including CDKs 4 and 6, at a
higher concentration. Besides CDKs 2, 3 and 5, moderate inhibition of CDKl and Gsk3b
was also observed. In contrast CDK5 is inhibited by GW8510 both in vitro and in vivo.
Since GW851 0 is not inhibiting the cell cycle CDKs, the neuroprotection may be by
other alternative mechanisms. IS 9l
Several2.arylidine and 2.hetarylidin derivatives. of the 1,4.benzoxazines class of
compounds (ASK2a and HSB-13) (Figure 1.4) are shown to be highly protective in
tissue culture models ofNeurodegeneration. ASK-2a was found to be neuroprotective in
primary granule neurons. Jnvitro CDK inhibition studies of both Ask 2a and HSB-13
shows that HSB-13 inhibits CDK1, CDK2, and CDK5. HSB-13, but Not ASK-2a. HSB13 is Protective against Oxidative Stress (Homocysteic Acid (HCA)-induced Neuronal
Death. HSB-13 protects hippocampal neuroblastoma HT22 cells and neurons against
HCA.I78 l ASK 2a is not neuroprotective on oxidative stress induced cell death. This
suggests that inhibition of CDKs is essential for protection against HCA-induced
neurotoxicity. HSB-13 reduced striatal degeneration and improved behavioral
performance in a chemically induced mouse model of Huntington's disease, and it
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protects against APP toxicity in flies. The ability ofHSB-13 to protect cortical neurons
against Ab-toxicity and against oxidative stress (HCA) and flies against the detrimental
effects of mutant APP suggests that this compound could have value in the treatment of
AD. The protection displayed by HSB-13 in an in vivo model ofHD suggests broad
neuroprotective efficacy.
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Figure 1.4. 3-substituted indolens for neuroprotection.

Indirubin and its derivatives were shown to be inhibits CDK5/p25 (IC50 = 10 nm)
and GSKb3( IC50 = 2 nm). [GJJ Indirubin-3'-monoxime (8, Figure 1.5) rescues spatial
memory deficits and attenuates

A~

associated neuropathology in a mouse model of AD.

lndirubins are very potent inhibitors of CDK5/p25. Furthermore, indirubin-3.monoxime
inhibits tau phosphorylation in vitro and in vivo at AD-specific sitesY 91 It also inhibits
A~- induced neurotoxicity in neuroblastoma.[&OJ
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Figure 1.5. Structure oflndirubin- 3 '- monoxime.

The accumulation of p25 results in overactivation of CDKS was related to Al3
toxicity. N-acetylcysteine (Figure 1.6) acts as a neuroprotector against the Al3 toxicity m
cultured cortical neurons by an increase in p35/CDK5 activity and attenuation of p35
proteolytic degradation. [SIJ

N-acetylcystein

Figure 1.6. Structure ofN-acetylcystein.

Although there are several recent repotis of CDKS inhibitors for potential
treatment of neurodegenerative disease, many of them are not extensively studied for
their neuroprotection and selectivity towards kinases. In recent times, compounds based
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on Quinazolines (6),[ 60-611 4.aminoimidazole (7),[621 6-oxo-1,6-dihydropyridines (9),[641
3,6-diamino-1H-pyrazolo[3,4.bpyridine derivative (10),[ 821 has been investigated for their
CDK5 inhibition and AP toxicity (Figure 1. 7).
Based on the crystallographic data of 12/CDK2 complex, Rzasa and coworkers
synthesized a series of3,4.dihydro-1H-quinazolin-2.ones (6, IC50 = 79nm) as
potent CDK5 inhibitors.[831 The 4.pyridyl moiety in these molecules form H-bonding to
the Asp144.Lys33 salt bridge to the inhibition ofCDK5. They are good inhibitors of
CDK2 as well. The selectivity of these compounds over CDK5 is less to moderate. [&JJ
The derivative of 4- aminoimidazole (7, IC50 = 64 nm and 11, IC50 = 9 nm)
compound has been shown to selectively inhibit the CDK5 over CDK2.[ 621 X-ray crystal
structure of compound 11 with CDK2 shows that [621 the amide carbonyl accept a
hydrogen bond from Lys33 and it interacts with a water molecule that bridges to the NH
of Aspl45. Lys33 and Asp145 (Asp 144 in CDK5) are the amino acid residue which in
present in the phosphate binding region of ATP. The compound 3,6-diamino-4.pheny11H-pyrazolo[3,4.b]pyridine-5-carbonitrile 10 inhibits CDK5(IC50 =0 .4nM) and GSK3P (IC50 = 1.5nM).[821
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Figure 1. 7. CDKS inhibitors, which are potential drugs in neurodegenerative diseases.

1.1.6

Cyclin Dependent Kinases: Structural Consideration. Cyclin-

dependent kinases (CDKs) are a family of 16 serine/threonine kinases that are key
regulators of the mammalian cell cycle.r661 CDKS is the main cyclin dependent kinase
which is targeted in AD. Due to it similarity with CDKl and CDK2 selective inhibition is
a challenging problem. An understanding of structure of CDKS and its mode of binding
will give an insight in to develop better drugs. Crystal structure of CDK5/p25 cleared the
mechanism of activation ofCDKS by p25.r 84l
The classical mechanism of CDK activation include binding of the cyclin box fold
and the phosphorylation of the activation loop known as T loop[SSJ by the CDK activating
kinase[ 86 -87 l. p25 contains a highly divergent CBF domain which elicits an active
conformation ofCDKS in the absence ofphosphorylation[841 . Mapelli and coworkers cocrystalized CDK5/p25 and three kinase inhibitors, (R)-roscovitine (Figure 1.3) (2),

IS

aloisine -A (Figure 1.8) and indurubin-3'-oxime(Figure 1.5).l661 These molecules ATP
competitive binders which bind to the well conserved catalytic loop of the kinase. Their
IC50 values are in the range of 0.1.0.2 mM. Smaller molecules such as aloisine A doesn't
fit to the back cleft of the ATP binding pocket resulting in reduced shape
complimentarily.

c:
N

OH

N

Aloisine-A

Figure 1.8. Structure of Aloisine-A.

Inhibitors affinity mainly arises due to the formation of hydrogen bonds and
hydrophobic interactions. In CDK5, the back bone carbonyl and amide of Cys83 serve as
a hydrogen bond acceptor and donor respectively. Crystals of CDK2 with inhibitors such
as roscovitine (2), olomoucine (3) and purvalanol B (Figure 1.13) showed similar pattern
of binding. But the orientation heterocyclic ring of these molecules in their complexes is
different. These orientations are different from adenine ring in APT/CDK2 complexes
itself. Different amino acids in binding loops of CDKS are involved in the binding of
different inhibitors to CDK5.
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1.1. 7

Stmctural Basis of CDK Inhibition. Cyclin dependent kinases belong

to a super family containing eukaryotic protein kinase (ePK) catalytic domain.1 88 "90l Most
of the protein kinases belong to this family have bilobal structure with N terminal
domain of approximately 85 residues, C terminal domain of approximately 170 amino
acid residues and a ATP binding cleft between the two lobes. 191 "921 They bind to

y phosphate of ATP though serine\ tlu·eonine\tyrosine hydroxyl groups. Activation of
kinases belong to ePK family are regulated by folding process of ePK domain. 193 l In
activation and deactivation of the kinases the active loop (T loop) under goes a
conformational change to form a platform for the interaction of kinase with substrate.
Activation loop is an approximately 20 amino acid residue located in the centre ofN lobe
and C lobe, where cyclin binding and phosphorylation takepalce. N lobe is reconstmcted
to generate a conformation to fit the ATP in the kinase active site. 194l
CDKs are an ePK subfamily of Serine/Threonine kinases. CDKS are activated by
binding to cyclins a regulatory subunit. Another process in the activation of CDKs is the
phosphorylation of the activation loop at a conserved tlueonine residue.1 86 • 95 "961 This is
the case with most of the members ofCDK family, including CDK2, CDKI, CDK4 and
CDK6. 1971 CDK5 differs from others activation mechanism. The binding of CDK5 cyclins
(cyclin D and E) doesn't lead to activation. Its activity is triggered by homologous
proteins p35 and p39, which are expressed only in neurons and a few other cell types.198 "
1001 CDK5 is also not activated by the phosphorylation of potential site Ser159 (Thr 160
ofCDK2) residue in the activation loop.

IIOI·IOZJ

In the case of CDK2, binding Cyclin A, remodels the kinase N lobe allow the
correct orientation of amino acid residues with ATP. 1941 For example, it pushes C helix
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(PSTAIRE helix) [1031 ofN lobe facilitating the interaction Lys33 and Glu51 is with

a and B-phosphates of ATP. Cylin A also locks the conserved Asp-Phe-Gly motif (DFG)
to a conformation that supports the function of this motif in the orientation of the aphosphate of ATP via a magnesium ion. Another step in the activation process is the
remodeling of the activation loop triggered via the phosphorylation ofThrl60 by CDKactivating kinase.[ 961 CDK2 is deactivated by phosphorylation ofT14 and Yl5, in the
glycine rich loop which is positioned opposite to the T loop. [I03l
Cyclins interact with CDK2 through a 100 amino acid residue structural motif
known as Cyclin box fold (CBF). Similarly p25 also has a CBF fold which binds the
activation loop around PSAALRE (PSTAIRE in CDK2) helix. Similar to cyclins p25 also
pushes the C helix to orient Lys33 and Glu51 for proper binding to ATP.

1.1.8

Mechanism of Binding of CDK Inhibitors. The majority of small-

molecule kinase inhibitors that have been developed so far target the ATP binding site,
with the kinase adopting a conformation almost identical to that used to bind ATP.
Selectivity is a major issue in this strategy. In this the molecules inhibit the kinase by
binding to the active DFG in conformation. A large conformational change for the
residues in the conserved Asp-Phe-Giy (DFG) motif in the active site of kinase is
required for the binding of the inhibitor. In all of the Ser/Thr kinase protein structures the
DFG motif assumes a conformation with the Phe residue buried in a hydrophobic pocket
in the groove between the two lobes of the kinase (DFG in conformation). The residues in
the pocket are highly conserved among the kinases. On binding to inhibitors the Phe
residue will move resulting in another conformation called DFG out conformation.P 04 l
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The adenine of ATP forms a crucial hydrogen bond with the hinge region of the
kinases in between theN- and C-terminallobes of the kinase domains while the end (3
and y phosphates of ATP are coordinated by a complex network of ionic and hydrogen
bonding interactions with several structural elements, including Mg2+ or Mn2+ ions, the
Asp side chain of the conserved DFG motif, and amino acid residues in the glycine-rich
loop located above the ATP binding cleft.
Adenine region of ATP forms hydrogen bonding with Glu81 and Leu 83 residue
of CDK2 in the active site. The carbonyl group of Gln 131 and Asp 86 act as a hydrogen
bond acceptor to the hydroxyl group on sugar moiety in ATP. In addition to these
hydrogen bonds, the phosphate groups engage in active hydrogen bonding with several
amino acid residues in the active site (Figure 1.9).
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CDK2/ATP

Figure 1.9. Major binding amino acid residues in CDK2 /ATP complex.

ATP competitive inhibitors typically form 1 to 3 hydrogen bonds with the kinase
hinge residues. The binding region of inhibitors can be divided in to adenine region,
ribose region, phosphate region and hydrophobic region. The adenine region can be
occupied by all the inhibitors although with different orientations than A TP. The ability
of inhibitors to extend in to hydrophobic region and other region is the key factor in the
specificity. The co-crystal structures of roscovitine (2), olomoucine (3), aloisine, inirubi n3 '-oxime (8) etc with CDK2 and CDK5/p25 have been reported (Figure 1.10 and Figure
1.11 ). (66, 105]
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CDK5/P25/ Roscovitine

B

Figure 1.10. Schematic diagram of major aminoacids involved in binding of roscovitine
(2) to CDK5/p25 (A). Crystal structure of CDK5/p25-roscovitine showing ligand
binding pocket. Hydrophobic region is indicated in red (B)[661 (PDB,
DOl: 10.221 0/pdbl unh/pdb).
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A

CDK2/Roscovitine

B

Figure 1.11. Schematic diagram of major aminoacids involved in binding of
roscovitine (2) to CDK2 (A). Crystal structure of CDK2.roscovitine ~2f showing ligand
pocket. Hydrophobic region is indicated in red (B). [I 6
(PDB, DOI:10.2210/pdb2a4Vpdb ).
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In the ATP pockets ofCDKS and CDK2 93% (27/29) of residues are conserved
and the two differing amino acid residues (Cys83 and Asp84 in CDKS; Leu83 and His84
in CDK2) have side chains that project away from the ATP pocket, thus reducing their
impact on inhibitor binding. Both CDK2 and CDKS conserve the Phe80 residue of the
hydrophobic pocket and maintain a Lys33.Aspl44 salt bridge the binding pocket of
CDKS.
In this CDK5/CDK2.inhibitor complexes different molecule have different
orientation in the active binding pockets. [IO?J In this review we will be comparing the
roscovitine (2) complexes of CDK2 and CDK5/p25, which is the most potent CDKS
inhibitor, currently under study. Roscovitine (2) is a planar molecule whose structure is
highly complementmy to ATP-binding cavity. In CDKS the carbonyl and the amide of
Cys 83 residue act as a hydrogen acceptor and donor respectively. The hydroxyl group of
roscovitine (2) is hydrogen bonded to Gln 130 amino acid residue. The ethyl groups are
buried in hydrophobic interactions with IlelO and Val18 (Figure 1.10).
The chiral C2-substiuent of roscovitine (2) in complexes with CDK5/p25 is
rotated around 182° around the N-C bond compared to the C2 of roscovitine (2) in
complexes with CDK2. [661 The large benzyl substituent is projected in to the hydrophobic
pocket lined by Ilel 0 and Phe82. The cyclic nitrogen N7 act as a hydrogen bond acceptor
to the NH of Cys 83. The backbone carbonyl oxygen act as a hydrogen bond acceptor to
the NH ofbenzylamino group in the purine ring.
In CDK2 complexes ofroscovitine (2), the hydroxyl group ofroscovitine (2) is
hydrogen bonded to water molecule. Leu 83 of CDK2 interacts with roscovitine (2)
through two hydrogen bonds. One nitrogen N7 act on roscovitne as a hydrogen bond
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acceptor for NH of Leu83 and the carbonyl group of Leu83 act as hydrogen bond
acceptor to the NH of benzylamino group on roscovitine (2). CDK2 maintains 20 vander
Waals interaction with the benzylaminogroup ofroscovitine (2) in complexes[IOGJ (Figure
1.11 ). This interaction is not shown by ATP in their complexes with CDK2. The main
residues involved in these interactions are !lelO, Phe82 and His84. The ethyl group is
interacting with hydrophobic environment.

1.1.9

Purine-Based Kinase Inhibitors. The purine derived cyclin dependent

kinase inhibitors got much attention due to its structural similarity to ATP itself. Among
them 2, 6, 9 substituted purines were found to be more active (Figure 1.12).
In I973, Lionel Rebhun and co-workers discovered 6-dimethylaminopurine(6DMAP, 13) as a protein synthesis enhancer which inhibited cell division in embryos.P 081
In 1980's the compound 13 was largely used as a nonspecific protein kinase
inhibitors.P 09 . 1101Rialet and coworkes found the IC 50 value of 6-DMAP as 120~1M. The
same group also found that plant hormone, N6-(y,y-Dimethylallyl)aminopurine, 14
(IC 50= 50f.!M, Table 1.1) another derivative of purine slightly more active that 6DMAP.P111 In a continues effort to find out specific more active inhibitors, Jaroslav
Vesely and coworkers studied the effect of the structural derivatives of6-DMAP (13)
and, N6-(y,y-Dimethylallyl)aminopurine (14) on protein kinases.
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13 (6-dimethylaminopurinc)

15 ( Purvalanol B)

14 (N-isopcntenyladenine)

16 (Amino purvalanol)

17 (Purvalanol A)

Figure 1.2. Structures of Purine based kinase inhibitors

But none of them showed any inhibitory effect (IC 50 >500~tM). Olomocine 3
(Figure 1.3) (2.(2.hydroxyethylamino)-6-benzylamino-9-methylpurine) and other C2, N6
and N9 substituted purines were found to exert strong inhibitory effect on CDKl, CDK2,
CDK5, erkl kinases but not on CDK4 and CDK6.

2
[II J

Olomocine (IC 50 =htM) was found to be an antimitotic reagent and it act as a
competitive inhibitor of ATP. Based on the structural activity relationship of more than
80 purine derivatives, Jaroslav and coworkers proposed the potential enzyme binding
sites of2, 6, 9substituted purine inhibitors. They proposed that Nl, N3 and N7 are
involved in hydrogen- bonding interaction and substitution at N9 and C2 are important
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for hydrophobic interaction directly with CDKs. The purine ring may be involved in the
hydrophobic interaction. l112 !
Structural modification of Olomoucine (3) led to the development of Roscovitine,
2. {[(l.hydroxymethyl)propyl]amino} -6-benzylamino-9-isopropylpurine, 2 which was
selective towards CDKl. Detailed analysis of molecular and cellular effects of purine
CDK inhibitors, supported by co-crystal analysis, has motivated several scientific teams
to continue with the synthesis and biological testing of2, 6, 9-trisubstituted purines.tmIISJ Gray and coworkers found that when benzyl amino group of roscovitine (2) is
replaced with 3.chloroanilino group in purvalanol A (17), the inhibitory activity increased
100-fold roscovitine (2). [IIGJ
The most potent compound known to date is purvalanol B. But it is inactive in
cellular assays which may be due to its lack of cell permeability.l 119 JA!though frequently
considered as rather selective for some CDKs (CDKl, CDK2, CDK5, CDK7, CDK9),
roscovitine (2) interacts with several other targets (DYRKlA, CKI, pyridoxal kinase),
although with a lower affinity. [121 - 122! Moravec and coworkers found that 2, 6, 8,9tetrasubstituted purines are not effective CDK inhibitors due to the rigid back part of the
active site of CDK2. [123!
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Table 1.1. IC50 (pM) of selected kinase inhibitors.

CDKll

CDK2/

CDK4/

CyclinB

CyclinA, E

CyclinD

0.45

0.7

14.2

0.16

[II?-IIS]Olomoucine (3)

7

7

>1000

3

[II 6lPurvalano1 B

0.006

>10

0.006

-

0.02

0.15

0.4

-

50(A)

>100

80

CDKs

CDK5/p25

[Ios. 117 lR-Roscovitine
(2)

0.006(A),
0.009(E)

[II 9lAminopurvalanol

0.033(A),
0.033
0.028(E)

[

120

lFlavopiridol (1)

0.06

[IISJNisopentenyladenine 45

1.1.10

Conclusions. Although there are several reported CDK inhibitors in the

literature for the treatment of other diseases such as tumor, not many of them are well
studied for their neuroprotective effect. Many of the CDK inhibitors tested such as
flavopiridol (1), roscovitine (2), butyrolactone 1 (4) and indirubins (8), although are very
potent inhibitors of CDK5/p25, act on targets

(GSK-3~),

apoptosis. Whether their dual specificity with

GSK-3~

other than CDKs while inducing

and CDK5/P25 is detrimental or

beneficial is still under debate. [63 · 124l No molecule which inhibits a single kinase has been
found out. This can be due to the structural similarities of the cyclin dependent kinases.
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Various side effects may arise because of the nonspecificty of those CDK inhibitors, which
can act on other cell cycle regulating molecules. Thus achieving high selectivity will be
one of the most important goals for the developments of new drugs.

1.2 PURINE-BASED FLUOROARYL-1,2,3.TRIAZOLES: SYNTHESIS AND
EVALUATION AS CELL CYCLE INHIBITORS IN ALZHEIMER'S
DISEASE
1.2.1

Introduction. The concept of abnormal neuronal cell cycle re-entry is

gaining increasing attention in recent years, as a major causative factor for AD. Cell cycle
dysregulation is accompanied by a variety of cascades including kinase upregulation,
DNA replication, and eventually leads to neuronal apoptosis. [l 2 s.J30J Cyclindependent
kinases (CDKs) are the protein kinases which regulate cell cycle, among which CDK5
plays a major role in the neuronal cell death as a result of abnormal cell cycle re-entry.
Overactivation ofCDK5, mediated by A p (Ap), results in tau-hyperphosphorylation,
decreased levels of synaptic markers, and cell cycle reactivation leading to substantial
neuronalloss.[2 IJ CDK5 in association with its principal activation protein p35 is
involved in functions such as neuronal differentiation and migration to synaptic
transmission. Intracellular oxidative stress leads to a rise in Ca2+ levels that activate
calpain resulting in the cleavage ofp35 to p25.P 31 l Thus selective inhibitors ofCDK5/p25
over CDK5/p35 are currently targeted, although there seems to be little success in this
regard.[44 • l3IJ A variety ofCDK5 inhibitors are currently under development as potential
therapeutics in AD and neuronal disorders. Structurally diverse compounds including
indole,£3 942 ] imidazole,[43 ' 44l pyrazolopyridine, [4SJ pyridopyrimidines/46 l piperidine/47l and

28

purine[48 "551 derivatives have been tested as CDK5 inhibitors. Among these compounds,
flavopiridol (1) and roscovitine (2) are currently undergoing clinical trials as therapeutics
in AD (Figure 1.13). [56 . 571

CH 3
I
N

?I

""
Cl

OH
OH

0

I
0
I

Ph/'--NH

OH

~N£J ;:~H
N

H 3C

N

~

CH3

N
H

2

Figure 1.13. Structures offlavopiridol (I) and roscovitine (2)

Fluorinated compounds are a major focus of current pharmaceutical interest.
Introduction of a fluorinated aryl groups into pharmaceuticals results in major
improvement in their therapeutic efficacy, presumably due to the hydrogen bonding
.
.
.
. s1tes.
. [132-1341 Fmi11er, fl uonnate
.
d
mteractwns
w1t. h t he fl uonnes
at t he enzyme active
drugs have additional advantages such as their enhanced solubilities, metabolic stabilities
and bioavailability. We have reasoned that by introducing a fluoroaryl group distant
from the nucleoside moiety, their selective CDK5 inhibitory effect, and hence neuronal
cell cycle suppression, could be improved. With that goal, we have now synthesized a
series of fluorinated purine-based triazoles and we have assayed their
neurotoxicity/neuroprotection in A~ incubated hippocampal slice cultures, using
fluorescence microscopy.
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1.2.2

Results and Discussion. Selective inhibition of CDK5/p25 over

CD5/p35 is a desired goal for the treatment of AD and other neurological disorders.
Roscovitine (2) is currently undergoing preclinical trials as kinase inhibitor in AD,
although it is not a selective inhibitor ofCDK5.1 571 Similarly, a flavone-derived
compound, flaovopiridol has also been shown to be effective as a broad-spectrum CDK
inhibitor. 11351 Perhaps due to this nonspecificity to selective CDKs, it is more cytotoxic
and has other harmful effects. 1136' 1371 It is therefore, desirable to design selective CDK
inhibitors that show neuroprotective effects, without attendant harmful side effects. We
have anticipated that by attaching the fluoroaryl rings to the roscovitine (2) analogues
through 1,2,3-triazole linkage, these compounds could be selective inhibitors of CDKs.
Click chemistry1138' 1391 is a convenient technique for tethering fluorinated and variously
substituted aryl moieties to purine derived alkynes. In this study, we have investigated the
neuroprotective effects of the fluoroaryl substituted purine based 1,2,3.triazoles along
with those offlavopiridol (I) and roscovitine (2), the current state-of-the-at1
pharmaceuticals 11401 for AD and related neurological diseases.
The neurotoxicity of A~ peptide arises primarily due to its overactivation of
CDK5.121 · 125 1 In turn CDKS, in association with aberrantly formed protein p25 (by
cleavage of p35), is responsible for neurodegeneration. Even though the involvement of
the p25 in the intracellular neurofibrillary tangle (NFT) formation is not well established,
its role in neuronal cell-cycle re-entry and resultant neuronal cell death is widely
established.i24 -251 Thus quest for kinase inhibitors is a reasonable alternative in the design
of AD therapeutics.ll 411 We have identified a convenient assay for neuronal cell death,
which could be artificially induced by incubation with A~ oligomers. The binding of
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propidium iodide (PI) with DNA of dead cells gives characteristic fluorescence which
could be followed by fluorescence microscopy. Since PI is impermeable to live cell
membranes, the observed fluorescence is indicative of the extent of dead cell populations.
Using this technique, we have found that incubation of hippocampal neuronal cells with
A~

results in significant neuronal cell death after duration of 48 h (Figure 1-15).

1.2.3 Synthesis. The triazole, 21, and its fluorinated derivatives, compounds
22.24, were prepared by the Cu(I) catalyzed 1,3.dipolar cycloaddition reactions of the
corresponding alkyne and azide substrates (Scheme 1.1 ). As expected, the products show
high 1,4.regiose1ectivity in these cycloadditions. Reaction of the commercially available
2,6-dichloropurine (18) with benzylamine gave 2.chloro-6-benzylaminopurine (19) using
a repotted procedure.r 142l Under our conditions, the reaction was complete in 15 min at 60
°C instead of the reported time of 3 h at ll 0 °C. Propargylation of compound 19 using
propargyl bromide in DMSO under mild conditions gave 2.chloro-6-benzylamino-9(2.propynyl)purine (20) regioselectively in high yield. The Cu(I) catalyzed azide-alkyne
click reaction[ 1431 (the 1,3.dipolar cycloaddition) of the alkyne 20 with fluorinated benzyl
azides, prepared in situ from their corresponding benzyl bromides, gave exclusively
1,4.disubstituted triazoles, 21-24.
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Scheme 1.1. Synthesis of purine-based fluoroaryl triazoles

The isomeric homogeneity of the product triazoles is readily verified tluough their
19

F NMR spectra (Figure 1.13). The pentafluoro triazole, 24, shows relatively shielded

o19F absorptions as compared to the monofluoro and the difluoro triazoles, 22 and 23
respectively, in accordance with similar observations for the monofluoro-, difluoro-, and
pentafluoroto luenes. l 1441
A~

is neurotoxic, and it can overactivate CDK5, which results in the tau-

hyperphosphorylation, cell cycle re-entry, resulting in neuronal apoptosis. Thus, we have
used A~ oligomers as the trigger of neurotoxicity in vitro for convenient assay of the
neuroprotective effects of the kinase inhibitors. Mouse hippocampal slice cultures were
treated with

A~

oligomers in the presence of PI as the staining agent. The degree of

hippocampal neuronal death was monitored by electron microscopic observation of the PI
uptake.
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The intensities of the fluorescence were conveniently analyzed using Scion
images. The intensity of the PI fluorescence reflects the relative number of the dead cells
as PI cannot permeate the live cell membranes. As shown in Figure 1.15, there is visible
difference in the control (in the absence of AP oligomers) and the AP oligomers-treated
cell cultures. Typically 48 his required for the expression of the AP toxicity. These
experiments were repeated using the established cell cycle inhibitors, roscovitine (2),
flavopirido1 (1 ), and the fluoroaryl substitued purine derived triazoles, compounds 22-24 .
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As can be seen in Figure 1.16, after 48 h of incubation time, roscovitine (2) and
flavopirido1 (I) and the o-fluorophenylmethyl-triazole, 22, have neuronal cell survival
rates comparable to those of the control experiments, i.e., those corresponding to the
cultures in the absence of the

A~

oligomers. Interestingly, the pentafluorotriazozle (24)

has virtually no neuroprotective effect, and the 2,6-difluoro- (23) and the nonfluorinated(21) derivatives have only marginal effects.

Control

A~1-42

oligomer 5~M
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2
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Figure 1.15. Time dependent response of PI uptake in hippocampal slices were recorded
over 48 h incubation after exposing hippocampal slice cultures to 5 ~tM A~ oligomers for
the indicated times. The PI uptake responses were quantitatively analyzed and shown as
graphs.
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Figure 1.16. Hippocampal slices were incubated with compounds 21.24, or cell
cycle inhibitors flavopiridol (1), roscovitine (2) (1 )..lM) for 1 hand then treated with 5
~~MAP oligomers in the presence of PI for 48 h. PI uptake vvas analyzed with microscopy
(panel A) to determine the effects of these pharmacological agents on AP oligomersinduced toxicity. The relative fluorescence intensities are expressed as arbitrary units of
PI uptake (panel B).
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1.2.4 Pretreatment of CBMFMT Suppresses the Neuronal Cell Cycle Reentry
Caused by A~ Oligomers. The alteration of cell cycle proteins expression with
pretreatment of the monofluoro compound (CBMFMT) was analyzed. The treatment of
CBMFMT significantly suppressed the induction of cyclin A and PCNA by
suggesting our new compound rescue

A~

A~

oligomer,

oligomer-induced neurotoxicity by inhibiting

cell cycle re-entry (Figure 1.17).
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Figure 1.17. CBMFMF suppresses cell cycle activation in response to A~
oligomer in hippocampal slices. (A) The effect of CBMFMT on A~ oligomer-induced
cell cycle activation. Slices were treated with CBMFMT (I pM), or Flavopiridol (I ~tM)
before the incubation with A~ oligomer for 24 h. Their pretreatment suppressed the
increased expression of cell cycle protein induced by A~ oligomer . Each number
represents the mean± S.E. from four different experiments. *,p<O.OS different from the
A~ oligomer-treated samples.
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1.2.5

Conclusions.

In summary, Af3 induced neurotoxicity in hippocamapal

cell cultures could be readily followed by fluorescence microscopy using PI assay, and
using this assay, we have demonstrated the Af3-induced neurotoxicity in neuronal cell
cultures. Through this fluorescence technique, we have shown that the roscovitine (2) and
flavopiridol (I) are efficient neuroprotecting agents. Further, the neuronal toxicity,
induced by the Af3-oligomers treatment of the cell cultures, could be effectively
suppressed in the presence of our mono-fluorinated purine based triazole, compound 22.
The pentafluorinated version, compound 24, is ineffective as neuroprotector, while
nonfluorinated triazole, compound 21, and difluorinated triazole, compound 8, although
relatively less effective than triazole 22, show some attenuation of neurotoxicity. More
impotiantly, the neuroprotective effect of compund 21 is comparable to those of the stateof-the-art

pharmaceuticals,

flavopiridol

(I)

and

roscovitine

(2).

The

monofluorocompound significantly suppressed the induction of cyclin A and PCNA by
Af3 oligomer, suggesting our new compound protects the neuronal cells from

Af3

oligomer-induced neurotoxicity by inhibiting cell cycle re-entry.

1.2.6

General Comments. Benzylamine (>99.5%), !.butanol (anhydrous,

99.8%), benzyl bromide (reagent grade, 98%) triethylamine (>99.5%), dimethyl sufoxide
(ACS reagent, >99.9%), potassium carbonate (ACS reagent, >99.9%), Copper(!) bromide
(98%), 2.flurobenzyl bromide (98%), 2,6-difluorobenzylbromide (97%),
pentafluorobenzylbromide (99%), and 2,6-dichloropurine (97%) were obtained from
Aldrich and used as received.
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1

H NMR spectra (400 MHz),

13

C NMR spectra (100 MHz), and 19F NMR spectra

(376 MHz) were obtained on a Varian Inova 400 MHz spectrometer in DMSO-D6
solutions ( Figure 1.18 - Figure 1.25). The digital resolution of the 1H spectra was
0.26Hz and

13

C spectra was 0.83Hz.

19

F NMR spectra were referenced to CFCh (8 19 F =

0), and 1H, and 13 C NMR were referenced to the residual solvent signals or internal
tetramethylsilane.All sample concentrations were ranged from Smg to 30mg in a volume
of0.7mL of deuterated solvent. 13 C spectra were obtained after 1024 scans and 1H NMR
spectra were obtained after 4 scans. El!MS was obtained using solid probe on a Hewlett
Packard HPs 5890 GC/MS instrument.

1.2.7

Synthesis Procedure. 2-Ch/oro-6-benzy/aminopurine (19).

To a

suspension of2,6-dichloropurine (110 mg, 0.52 mmol) inn-butanol (3 mL), benzylamine
(57 mg, 0.52 mmol) and triethylamine (72 mg, 0.79 mmol) was added. The mixture was
stirred and heated at 60 °C for 15 min. The resulting precipitate was filtered, washed with
water (20 mL) and methanol (10 mL), and air-dried overnight. Compound 19 (130 mg,
95%) was obtained as an off-white solid: mp 262 °C; EI/MS (m/z (relative%)): 259 (19,
M+), 260 (14), 261 (17 %), 106 (100), 91 (77); 1HNMR (400 MHz, DMSO) 8 8.15 (s, 1
H), 7.25-7.34 (m, 5 H), 4.66 (d, JH·H= 6Hz, 2 H);

13

C NMR (100 MHz, DMSO) 8 155.0

(s) 153.1 (s), 150.7 (s), 140.2( d, 1Jc.H= 200Hz), 139.6 (s), 128.5(d, 1Jc.H =158Hz,
127.5 (d, 1Jc.11 = 157 Hz), 127.0(d, 1Ic.H =158Hz) 118.1 (s), 43.4 (t, 1Jc.H =139Hz)).
2-Ch/oro-6-benzylamino-9-(2.propyny/)purine (19).

A solution of

2.chloro-6-benzylaminopurine (1.1 g, 3.8 mmol), in DMSO (5 mL) was cooled to 0 °C,
potassium carbonate (0.79 g, 5.7 mmol) and propargyl bromide (0.45 g, 3.8 mmol) was
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added to the contents, and stirred for 1 hat 0 °C. Water (20 mL) was then added to the
reaction mixture, and the resulting yellow precipitate was filtered and washed with excess
water (50 mL). Compound 20 (1.1 g, 80%) was obtained as an off-white solid upon
successive recrystallization from dich1oromethane and ethyl acetate: mp 180 °C; EI/MS
(m/z (relative%)): 297 (63, M+), 298 (15), 299 (23), 258 (46), 91(100); 1H NMR (400
MHz, DMSO) o 8.23 (s, 1 H), 7.21-7.38 (m, 5 H), 5.03 (bs, 2 H), 4.62 (d, J 11•11 = 6Hz, 1
H), 3.51 (s, 1 H).

Be NMR (100 MHz, DMSO) o 155.6 (s),

154.0 (s), 150.3 (s), 140.7 (d,

1Jc. =214Hz) 139.9 (s), 128.9 (d, 1Jc. =159Hz), 127.9 (d, 1Jc. =157Hz), 126.8 (d,
11
11
11
1Jc-H =158Hz), 118.1 (s), 78.5 (t, 2Jc. = 9Hz) 76.7 (dt, 1Jc. = 252Hz, 2Jc. = 4Hz),
11
11
11
43.8 (t, 1 Jc.H = 126 Hz), 33.3 (t, 1 Jc.11 = 139Hz).

2-Chloro-6-benzylamino-9-(1. benzyl-] H-1, 2, 3. triazol-4.yl-methyl)purine
(21). Benzyl bromide (11 0 mg, 0.58 mmol) was added dropwise to a solution of sodium

azide (42 mg, 0.64 mmol) in DMSO (5 mL, and stirred at room temperature for 15 min.
Compound 20 (173 mg, 0.58 mmol), triethylamine (6 mg, 0.06 mmol) and CuBr (8 mg,
0.6 mmol) were added to the contents in that order, and the reaction mixture was stirred
at room temperature for 30 min. The reaction mixture was poured into ice-cold water (20
mL), and the resulting off-white precipitate was filtered and washed with dilute NH40H
(20 mL) and water (50 mL) to give the compound 21 (200 mg 80%) essentially pure by
NMR; mp 235 °C. EIIMS (m/z (relative%)): 430 (32, M+), 431 (11), 432 (13), 258 (54),
1
(100); HNMR(400MHz, DMSO)o 8.23 (s, 1 H), 8.15 (s, 1 H), 7.40-7.17 (m, 10H),
5.56 (s, 2 H), 5.40 (s, 2 H), 4.62 (d, h1-H= 6Hz, 2 H);

Be NMR (100 MHz, DMSO) li

155.6 (s), 153.9 (s), 150.3(s), 143.1(d, 1Jc.H =199Hz), 141.9 (s), 139.9 (s), 136.51(s),
1
129.4 (d, 1Jc.H =160Hz) ,128.9 (d, Jc.11 = 159Hz), 128.8 (d, 1Jc. 11 =159Hz), 128.5 (d
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Jc-H =158Hz), 127.9 (overlapping doublets), 127.4 (overlapping doublets), 124.4 (d,

,

Jc-H =200Hz) 118.6 (s), 53.4 (t, 1Jc_H =145Hz), 43.7 ((t, 11c-II = 135Hz), 38.9 (t, 1Jc_

1

H=139Hz).

2-Ch/oro-6-benzy/amino-9-[1. (2.j/uorobenzyl)-1 H-1, 2, 3. triazol-4.ylmethyl]purine (22).

Compound 22 was obtained as an off- white solid (85%), using

procedure A: mp 240 "C; EVMS (m/z (relative%)): 448 (44, M+), 449 (14), 450 (17),
258 (83), 109 (100), 91 (67); 1H NMR (400 MHz, DMSO) 8 8.23 (s, I H), 8.17 (s, I H),
7.43-7.10 (m, 9 H), 5.60 (s, 2 H), 5.38 (s, 2 H), 4.60 (d, JH-II= 6Hz, 2 H);
(376MHz, CDC~}) -117.37 (dd, 1JH-F= 14Hz, 2JH-F= 8Hz);

13

19

F NMR

CNMR(IOOMHz,

DMSO) 8160.7 (d, 1Jc_F=248 Hz), 155.6 (s), 153.8 (s), 150.3 (s), 143.1 (d, 1Jc-H = 199
Hz), 142.0 (s), 139.9(s), 131.4 (d, 11c-H =165Hz) 131.3 (d, 1Jc-H =160Hz, 3JcF =4Hz),
128.9 (d, 1Jc-H =156Hz) 127.9 (d, 1Jc.H =150Hz), 127.4 ( d, 1Jc-H =160Hz), 125.5 (d,
1

Jc-H =150Hz), 124.5 (d, 1Jc-H =200Hz), 123.3 (d, 2JcF =26Hz), 118.6 (s), 116.2 (d,

JCH =170Hz, 2Jc-F =21Hz) 47.6 (t, 1Jc-II = 130), 43.8 (t, 1Jc_H =133Hz), 38.9 ( t, 1Jc-H
=143Hz).

2-Ch/oro-6-benzy/amino-9-[1. (2, 6-dij/uorobenzy/)-1 H-1, 2, 3. triazol-4.ylmethyl]purine (23).

Compound 23 was obtained as an off white solid (84 %), using the

procedure similar to that for compound 21: mp 239 "C; EI/MS (m/z (relative%)): 466
(52, M+), 467 (19), 468 (22), 258 (77), 127 (100), 91 (73); 1H NMR (400 MHz, DMSO)
8 8.20 (s, 1 H, purine CH ), 8.16 (s, 1 H, triazole CH), 7.05 -7.47 (m, 8 H, phenyl), 5.60
(s, 2 H, benzylic CH2 attached to triazole), 5.37 (s, 2 H, N9-CH2), 4.61 (d, J = 5.5 Hz, 2
H, NHCH2).

19

F NMR (376 MHz, CDCh) 8-114.10 (t, J= 7.0 Hz).

13

C NMR (100 MHz,

DMSO) 8 162.5, 160.2, 155.4, 153.7, 150.3, 142.8, 141.8, 140.0, 132.4, 128.8, 127.9,

40
124.6, 118.4, 112.7, 112.4 (aromatic carbons) , 43.7 (benzylic-C attached to the amino
group), 41.4 (benzylic-C attached to triazole ring), 38.6 (N9-CHz).
2-Ch/oro-6-benzy/amino-9-[1. (pentajluorobenzy/)-1 H-1, 2, 3. triazol-4.ylmethy/]purine (24).

Compound 24 was obtained as an off- white solid (89 %), using

the procedure A: mp 225 °C; EIIMS (m/z (relative%)): 520 (24%, M+), 521 (6), 522
(9%), 258 (73), 181 (69), 106 (64), 91(100); 1H NMR (400 MHz, DMSO) o8.22 (s, 1 H),
8.23 (s, 1 H), 7.32.7.19 (m, 5 H), 5.73 (s, 2 H), 5.39 (s, 2 H), 4.61 (d, JH-H = 5.5, 2 H); 19F
NMR (376 MHz, CDCh) o-141.70 (dd, 1h-F = 23.2, 2h.r = 7.2 Hz, or/ha-fluorines),152.7 (t, JF-F =22Hz, para-fluorine), -161.43 (dt, 1h.r = 22.9, 2Jr.F = 7.4 Hz, metafluorines);

13

CNMR(101 MHz, DMSO)

o 155.5 (s), 153.8 (s), 150.3 (s), 145.6(dm, 1Jc_

r =254Hz), 143.14 (s), 142.01 (d, 1Jc.11 =199Hz,), 141.6 ( dm,, 1Jc-F =259Hz),
137.7 (d, 1Jc-F = 249Hz), 139.9 (s), 128.9 (dd, 1Jc-H =159Hz, 2Jc-H =6Hz), 127.9 (dm,
1
1
1
Jc-H =154 Hz),127.5 (dt, Jc-H =164Hz), 124.8 (d, Jc-H =197Hz,), 118.8 (s), 109.8 (t,
3
1
2
1
Jc.F =18Hz, J c-F =3Hz), 43.8 (t, Jc.H =139Hz,), 41.1 (t, Jc.11 =130Hz), 38.8 (t,
1
Jc-H =142Hz).

1.2.8

Preparation of A~ Oligomers. Soluble A~ oligomers were prepared as

described previously.l 1451 Briefly, 1.0 mg of A~ 1.42 peptide was dissolved in 120 ~1L of
hexafluoroisopropanol for 60 min at room temperature, and placed back on ice for 5-10
min. Hexafluoroisopropanol was evaporated overnight in the hood at room temperature.
The sample was dissolved in 100% DMSO by adding 20

~tL

fresh anhydrous DMSO

(Sigma Hybri-Max) to 0.45 mg peptide, and diluted 5 mM peptide stock into medium.
Diluted peptide was incubated at 4 °C for 24 h, and then centrifuged at 14,000 g for 10

41
min in the cold. Before treating slice culture with

A~

oligomers, the oligomers were

incubated at room temperature for 20 h.

1.2.9

Preparation of Hippocampal Slice Cultures. Organotypic

hippocampal slice cultures were prepared as described previously.P 46l Briefly,
hippocampal slice cultures were prepared from 7-10 day-old mouse pups. Slices were cut
at 400 f!m on a Mcllwain tissue chopper, transferred to Millicell (Millipore Corp.,
Bedford, MA) membrane inserts (0.4

~un),

and placed in 6-well culture plated. The upper

surfaces of the slices were exposed to a humidified 37

oc atmosphere containing 5%

C02 . Slice culture media consisted of basal Eagles medium with Earle's balanced salt
solution, 20% heat-inactivated horse serum, enriched with glucose to a concentration of
5.6 mM. The medium was changed every other day. Slices were examined periodically
for viability, and any dark or abnormal slices were discarded.

1.2.10 Experimental Treatment of A~ Oligomers to Organotypic
Hippocampal Slice Culture. The effects of A~ oligomers were tested in the slices
which had been maintained for 15-20 days in vitro. All reagents were added to serum
free medium (no horse serum).

A~

oligomers were added to cultures in serum free

medium. Vehicles were treated the same way except with no peptide. The slices were
pretreated with compounds 21, 22, 23,24 or cell cycle inhibitor flavopiridol (1) or
roscovitine (2) (1

~tM)

for 1 h before

A~

oligomers treatment.

42

1.2.11

Assessment of Neuronal Cell Death by PI Staining. To analyze the

degree of hippocampal neuronal cell death, hippocampal slices were stained by adding
Propidium Iodide (PI) into slice culture medium at a concentration of 5 ~tg/mL. At
indicated times after

A~

oligomers treatment, the degree of hippocampal neuronal death

was evaluated by microscopic observation of PI uptake as described previously.[SJJ
Images were acquired through an AxioCam camera on an Axiovert 200M microscope
(Zeiss, Thornwood, NY). The intensity of the fluorescence was quantitatively analyzed
using Scion Image. The images were expressed as an arbitrary unit of PI uptake.

1.2.12 Protein Extraction and Western blot Analysis. The western blotting
analysis was performed as described previously [147 l. After A~ oligomer treatment, these
slices were rinsed twice with ice-cold PBS and then lysed in ice-cold lysis buffer. The
protein concentration was determined by the method ofBCA (Pierce). Equal amounts of
sample proteins were separated according to their molecular weight on 10 or 12% SDSpolyacrylamide gel and transferred onto polyvinylidene difluoride membranes. The blots
were blocked with I 0% milk in TBS-T for I h at room temperature, and then treated with
primary antibodies diluted with I% milk and incubated overnight at 4 °C. The following
antibodies were used: anti-PCNA (I :1000; Santa Cruz), anti-cyclin A (I: 1000; Abeam).

43

1.2.13 Statistical Analysis. Data were expressed as the means + S.E. ofthe

values from the number of experiments indicated in the corresponding figures.
Differences between groups were exam ined for statistical significance using one-way
analysis of variance with an unpaired Students t-test. A p value less than 0.05 denoted
statistical significance.
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2. NMR STUDIES OF TRANSITION METAL ION BINDING TO
HISTIDINE, GLUTAMIC ACID AND ASPARTIC ACID: THE
POTENTIAL METAL ION BINDING SITES OF AMYLOID-p
PEPTIDE.

2.1

INTRODUCTION

2.1.1

Role of Metal Ions in

AP Toxicity.

Transition metal ions, mainly

Fe(III), Cu(Il), and Zn(II), are localized in amyloid-P (Ap) plaques and neurofibrillary
tangles in Alzheimer's disease (AD).ll- 61The oxidative stress arising as a result of the
metal ion binding to the AP peptide is still debatable, although more recently a unified
hypothesis involving oxidative damage through mitotic insults and metal ion induced
oxidative stress on AP and neurofibrillary tangles is gaining much attention.P- 81 At low
concentrations of the transition metal ions, the AP shows antioxidant activity due to the
sequestration of the metal ions from the surrounding tissue environments, whereas at
relatively higher concentrations, the metal ions serve as active sites for the Fenton-HaberWeiss reaction, which results in onset of oxidative stress.l 9- 111 The highly redox active
Cu(Il) and Fe(II) are thus not only responsible for the formation of AP aggregates, but
also in subsequent overproduction of reactive oxygen species (when bound to AP
peptide) which have deleterious physiological consequences. Highly redox active Fe(III)
and Cu(II), as AP complexes, are involved in the neurotoxicity, while the relatively less
Fenton-active Zn(II) may be neuroprotective or neurotoxic depending on the
concentration levels. 14• 6• 121Many reports have suggested that low concentrations of
Zinc(II) stabilize AP in the oligomeric form, restricting further polymerization into the
fibrillary form_l 13 - 141 This may in fact be detrimental as the oligomeric forms of AP have
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been shown to be neurotoxic and the fibrillary forms relatively less harmful. While
circulating levels of Zn(II) may be appear too low for such interactions, synaptic activity
produces pulses of free Zn(II) release. [141 The immediate formation of Zn(II)-Ap oligomer
complexes may also directly affect synapse activity within the brain, as they bind directly
to synapses, co localize with synaptic markers, interfere with synaptic function, and
correlate with synaptic loss.[ISJ Although Zn(II) ions play a crucial role in AD, its
relatively binding efficiency compared to Cu(II) and Fe(III) has not been clearly
demonstrated to date. A variety of metal-ion chelators such as clioquine and
desferrioxamine are currently introduced as therapeutics in AD on the assumption that the
transition metal ions released from the AP plaques play a key role in the oxidative stress
in AD.

[1 6- 171

2.1.2

NMR Characterization of Metal Ion Binding Site of Ap. Recent 1H

nuclear magnetic resonance (NMR) and electron spin resonance (ESR) studies show that
histidine residues of AP bind to Zn(II) through the imidazole nitrogens ofHis6, His13,
and His14 residues of Ap. [2, 91X-ray absorption fine structure spectroscopy of histidineZn(II) complex shows the binding ofZn(II) mainly tlu-ough the imidazole nitrogen(Nl)
and the amino group. [ISJThe hydrophilic region of Ap 128 has three histidine residues (H6,
13, 14) which are mostly responsible for the strong metal ion binding, although other
carboxylate side chain amino acids, aspmtic acid and glutamic acid and the hydroxyl
. [2 · 13· 19-241 R ecent stu d'1es usmg
. s1te
.
. may exert some b'm d'mg affi1mty.
group of tyrosme

specific N-15 and C-13 labeling show histidine as the major ligand for Cu(II) ionP 51
Further, the 1H NMR spectra of uniformly 15 N-labeled AP140 show up field shifts for the
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side chain imidazole-C2 hydrogens ofhistidines (H6, Hl3, and Hl4), ret1ecting
presumably rapid conformational changes for the

A~1 4 o

peptide during metal ion

binding. 1261 Thus the mode of binding ofZn(II), Fe(III), and Cu(II) to A~ 1 .4o could not be
established through the use of either the smaller peptide fragments

(A~u 6 , A~u 8 )

or

AP140 peptide itself.
As far as we are aware there are no systematic studies of the relative strengths of
the Zn, Fe and Cu ion binding to the AP peptide. NMR methods are ideally suited for
direct estimation of binding strengths. However, the paramagnetic nature of the Fe(II),
Fe(III), and Cu(II) causes appreciable line broadening at the concentrations required for
determining their binding stoichiometry. Zn(II) is diamagnetic and in the absence offast
intermolecular exchange would give reliable NMR data for its complexes. Metal ions that
bind stronger than Zn(II) are expected to show deshielded absorptions for hydrogens near
the coordination site. Further, peak broadening due to the added paramagnetic Fe(III),
Fe(II) or Cu(II) species indicate their displacement of Zn(II) ions from the Zn(II)complex. Thus using histidine (H), tyrosine (Y), aspartic acid (D), and glutamic acid (E),
which are the potential metal ion binding centers in the hydrophilic region of A~, we
have probed their relative binding efficiencies of Zn(II), Fe(III), Fe(II), and Cu(II)
species.
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2.2

METAL ION BINDING STUDIES OF HISTIDINE, GLUTAMIC ACID
AND ASPARTIC ACID: RESULTS AND DISCUSSION
AP peptide binds transition metal ions, such as copper, zinc, and iron. At low

concentrations of these metals, AP acts as antioxidant through removal of the metal ions
from the surrounding cellular environments. On the other hand, when coordinated to
larger amounts of the metal ions, it acts as pro-oxidant through Fenton reactions of the
associated metal.[IOJ Although the nature of the metal ion complexation and its resultant
effects on oxidative stress are currently under debate, it is impot1ant to know the relative
binding strengths of the metal ions to Ap. N-tenninal domain, 1.28 (underlined on the
sequence below), of AP is hydrophilic with potential metal ion coordinating amino acids,
aspattic acid, glutamic acid, tyrosine and histidine as shown below.
1 DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA 42

The remarkably high affinity of Cu(Il) to Ap, as shown by fluorescence titration
methods, indicates that Cu(II) is central to the neurotoxicity.[27 J A recent study, involving
selective N-15 and C-13 labeling of glutamic acid and alanine, respectively, shows that
H6, H13, H14, and carbonyl oxygen of A2 bind to Cu(II) in a square planar structure.l2 51
Futther, it was found by these site specific labeling studies that Y1 0 hydroxyl is not a key
ligand at physiological pH range. [lSI On the other hand, other studies show the
importance of glutamic acid and aspartic acid residues in the coordination of metal
ions.[281
From the above discussion, it is evident that histidine residues in Ap are the major
binding sites for the metal ions, and in order to understand the relative binding
efficiencies of Cu(Il), Zn(II) and Fe(II) to Ap we have used histidine as a model
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aminoacid and estimated its metal ion binding strengths through NMR titrations. We
have also compared the metal ion binding efficiencies of aspartic acid, glutamic acid and
tyrosine by this method. Earlier NMR studies of Zn(II) complexation of AP or its
hydrophilic fragments (1-28 or 1-16) revealed significant peak broadenings of histidine,
aspmtic acid, and glutamic acid residues, but there were no clear cut deshieldings of the
NMR absorptions, presumably due to the rapid conformational changes of the peptides
upon metal ion complexation. [! 9-20• 291 Therefore, we chose histidine as a model amino
acid and compared its relative metal ion chelating efficiencies towards Zn(II), Fe(II),
Fe(II)), and Cu(II) at physiological pH and ambient temperatures.
We have chosen Zn(II) ions initially for our NMR studies because it is
diamagnetic; there will not be significant signal broadening in the measured range of
concentrations required for the saturation of the binding sites. The 1H NMR spectra for
incremental addition of Zn(II) to histidine in phosphate buffer (D 20) (Figure 2.1) shows
deshielded absorptions for all the histidine protons.
Significantly large deshieldings were observed for

o1H 7.49 (C2.imidazole H)

implying strong coordination through Nl.imidazole nitrogen. Both amino and carboxy
groups may be involved in coordination, as the

o1H at 3.74 and diastereotopic hydrogens

at C3 (o 1H 2.92) are also deshielded by relatively smaller extent.
Mol ratio plots of [Zn(II) ]/[His) and chemical deshielding for

o1H for

C2.imidazole hydrogen (Figure 2.2) show a stoichiometry for Zn(II):His of I :2, from the
abrupt changes in the slope [301 • Based on this data we propose an octahedral structure (1)
for Zn(II)-histidine complex (Scheme 1). Earlier x-ray structures for related Cu(Il)-
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histidine complexes were shown to involve equilibrating square pyramid and square
planar structure with 2:1 histidine-Cu(II) stoichiometry.P IJ
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Figure 2.1. 1H NMR titration of histidine with Zn(ll) in D 20 (8 H (020) =
4.63ppm) solution at 25 °C and at a pH of7.45 ± 0.01. Spectrum A is for histidine
dissolved in phosphate buffered 0 2 0 (pH 7.45); spectra B toN are for incremental
additions of Zn (II) to histidine solution (A); in each of these later solutions the [Zn(II)] I
[histidine] ratios are as follows: B, 0.05; C, 0.10; D, 0.15; E, 0.2; F, 0.31; G, 0.52; H,
0.73; I, 1.04; J, 1.25; K, 1.41; L, 1.99; M, 3.91; N, 5.75. The absorption at 8 1H 7.49
corresponding to imidazole-2H was relatively most deshielded indicating strong binding
of histidine tlu-ough imidazole-N3. From the spectral changes it is evident that other
binding sites of histidine are the amino and carboxyl groups.

69
0.6

0.5

•

•

0.4

[Zn 2'] : [His] = 1:2

s

"' 0.3
Q,

~

02

0.1

0~----------~------------~------------~----------~

0.0

0.5

1.0

1.5

2.0

(Zn,.(/(llis]

Figure 2.2. Mol ratio plot for the incremental addition of Zn(II) to histidine. The
concentration of histidine is kept constant at 92 mM and Zn(II) concentration was varied
from 0 to 6 molar equivalents. The stoichiometry of Zn(II) to histidine was found to be
I :2 as indicated by the abrupt changes in slope of the curve.

Incremental addition of Zn(II) (0 to I equiv.) to glutamic acid (50 mM) and
aspartic acid (40 mM) solutions in phosphate buffer (DzO) showed no chemical shift
variations, implying non-binding of these amino acids with Zn(II).These data are not in
agreement with the NMR studies ofZn(II) complexation with human and rat

A~ us

by

Gaggelli and coworkers' who reported chemical shift variations for the aspartic acid
(D 1) and glutamic acid (E 11) upon Zn(II) complexationY 91 The conformational changes
of A~ induced by Zn(II) may explain the discrepancies as we have used the individual
amino acids in our studies. Zirah and coworkers' TOCS Y NMR studies of Zn(II)
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complexation of A~ 116 showed no chemical shift variations but based on the line
broadening of the peaks they have inferred the coordination ofH6, Hl3, Hl4, Ell
residues to Zn(ll).[ZOJ Our observation of the significant downfield shifts of histidineC2.imidazole hydrogens confirm the involvement of histidine residues in the Zn(Il) ion
binding (Scheme 2.1 ). These observations imply the major role of histidine residues in
the binding to Zn(Il) ions, also in accordance with the recent experimental observations
on A~ peptideY 31

0

C2-imidazole

3

2

COOH

HO
4

Glutamic acid (E)

3

HO

H

2

1
COOH

Cl

1

0

Aspmiic acid (D)

Scheme 2.1. Structures of the proposed octahedral His-Zn(II) complex (1 ),
glutamic acid (E), and aspartic acid (D); the carbons are numbered in accordance with the
descriptions in the text.
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2.2.1

Relative Binding Efficiencies of Fe(III), Cu(II) and Zn(Il). In order

to investigate the relative binding efficiencies of iron and copper ions, in separate
experiments we have titrated the Zn(Il)-histidine complex solutions (phosphate buffer,
pH 7 .4) with Fe(III) and Cu(Il) salts. Upon addition of 0.1 mol equivalents of Cu (II) to
Zn(II)-histidine (0.5: 1 molar ratio) solution, the absorptions at

o1H 7.9 and 6.9 have

slightly shifted downfield (0.12 ppm and 0.1ppm respectively) and are significantly
broadened due to the paramagnetic nature of the Cu(II) species (Figure 2.3). The peak
broadening, as well as slight deshielding effect at this concentration level, show that
Cu(Il) is relatively more efficient than Zn(Il) in binding to histidine.

Histidine:Zn(II):Cu(Il)=l :0.5:0.1
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Figure 2.3. Partial 1H NMR spectra ofhistidine-Zn(II)/Cu(I!). Titration of
Cu(II) solution to Zn(II)-histidine solution resulted in significant line broadening even at
8.3 mM range (0.1 mol eq ofCu(II)) due to its paramagnetic character. The sight
deshielding and line broadening indicate competing replacement of Zn (II) by Cu(Il)
from its complex.
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Similarly, addition ofFe(III) to Zn(Il)-histidine in phosphate buffer (pH 7.4)
shows significantly deshielded peaks (Figure 2.4), which indicates much stronger binding
efficiency ofFe(III) to histidine as compared to Zn(Il). In accordance with this'evidence,
addition of0.5 mol equivalents ofFe(III) to 92 mM solution of pure histidine in
phosphate buffer (pH 7.4) resulted in deshielding of the peak at o1H 7.5 to 8.5 (L'Io = 1;
Figure 2.4).
Under similar conditions, the Zn(Il) complex showed relatively smaller chemical
shift difference of (L'Io = 0.5). The observed significant deshielding for Fe(III) complexes
supports the greater binding affinity ofFe(Ill) to histidine as compared to Zn(Il). In a
control experiment, reverse addition of Zn(Il) to a solution ofhistidine-Fe(III) resulted in
no changes in the 1H NMR chemical shifts, further confirming the relatively higher
binding efficiency of Fe(III) over that of Zn(Il).
In a separate experiment we have also titrated Cu(Il) chloride and Fe(II) sulfate
to histidine solution (phosphate buffer, pH 7 .4). Due to the high paramagnetic nature of
the Cu(Il) species we were able to obtain NMR spectra for solutions up to 0.1 mol
equivalents of Cu(II). Even at this relatively low concentration of Cu(II), the imidazoleC2.H and imidazole-C5-H of histidine were significantly deshielded by 0.57 and 0.27
ppm, respectively.
Addition of 0.1 mol equivalents of Fe( II) to histidine solution resulted in
downfield shift of the imidazole-C2.H and imidazole-C5-H by 0.22 and 0.15 ppm,
respectively.Under similar conditions titration ofFe(Ill) chloride with histidine solution
shifted the imidazole-C2.H and imidazole-C5-H of histidine downfield by 0.45 and 0.15
ppm, respectively (Figure 2.5).
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Figure 2.4. Partial 1H NMR spectra ofhistidine-Zn(II)/Fe(Ill). As Fe(III) was added to a
Zn(II)/histidine solution the absorptions for the imidazole protons were broadened and
were shifted to downfield indicating relatively stronger binding affinity ofFe(III) over
Zn(II).
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Figure 2.5. 1H NMR spectra ofhistidine/Fe (Ill). Addition of0.5 mol equivalents of
Fe(III) to histidine resulted in significantly downfield shifts for the imidazole hydrogens
as compared to similar titration with Zn(Il) under similar conditions. The relatively much
deshielded absorptions indicate higher binding efficiency for Fe(Ill) as compared to
Zn(Il). Maximum concentration ofFe(III), which could be used for these NMR binding
studies was 0.5 mol equivalents due the broadening of the peaks.

Titrations of Zn(Il) with histidine under same conditions resulted in downfield
shifts for C2. and C5- imidazole hydrogens by 0.2 ppm and 0.1 ppm, respectively. From
the observed deshielding of the C2.imidazole hydrogen in the above experiments, the
relative binding efficiencies of the metal ions to histidine is in the following order:
Cu(II) > Fe(Ill) > Fe(II) > Zn(II).

Overall, these results indicate superior complexing

ability of iron and copper ions over zinc ions.
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2.2.2

Relative Metal Ion

Binding Efficiencies of

Glu, Asp and Tyr.

The hydrophilic region of A~ 128 contains, in addition to histidine, other potentially
metal ion coordinating amino acids, Glu(3, 11,22), Asp(!, 7,23), and Tyr(l 0). In order to
evaluate their relative metal ion binding efficiencies we have performed similar proton
NMR titration studies for these amino acids. Metal ion complexation to the side chain
carboxyl groups of these amino acids would be expected to deshield the hydrogens on its
neighboring carbons (C4 and C3 forE and D, respectively). Upon addition ofFe(III) (0.3
equivalents) to buffered glutamic acid (50mM) and aspartic acid (40mM) solutions in
D20, the C4.protons of glutamic acid and C3 protons of aspartic acid were deshielded by
0.05 ppm and 0.07 ppm, respectively (Figure 2.6). Under comparable conditions (i.e.,
histidine: Fe(III) = I : 0.3) histidine-C2.imidazole hydrogens were deshielded by 1 ppm,
showing relatively much greater coordinating ability of histidine groups.
Thus, the relative binding efficiencies of glutamic acid and aspartic in

A~

are

insignificant as compared to that of histidine. These findings are in accordance with
recent hyperfine sublevel con·elation spectroscopy studies of site specifically N-15 and
C-13 labeled A~ peptide which show complexation mainly by histidine residues. 1251
The results on tyrosine are not conclusive due to its relative insolubility in water,
but overall there are no significant chemical shift variations for tyrosine in the presence
ofFe(I!I), also in accordance with the recent 1H NMR studies of A~ 1 .4 0 peptide.1 261
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Figure 2.6. 1H NMR spectra of glutamic acid/Fe(III) (top) and aspartic
acid/Fe(III) (bottom). Addition ofup to 0.3 mol equivalents ofFe(III) to glutamic acid
and aspartic acid resulted in relatively minor deshielding of the chemical shifts, as
compared to histidine, showing relatively weak binding affinity of these amino acids with
Fe(III).

2.2.3

Conclusion. As a model to the metal ion binding to AP peptide, we have

investigated the relative binding efficiencies of Fe(III), Cu(Il), and Zn(ll) to histidine,
tyrosine, aspartic acid and glutamic acid using 1H NMR titration experiments. From the
observed deshielding of the chemical shifts it is evident that histidine is the major binding
site for the metal ions. We have found a stoichiometry of Zn:histidine of 1:2, suggesting
an octahedral structure to the complex. From NMR titration experiments it can be
concluded that the Fe(III)/Fe(II) and Cu(ll) bind relatively more strongly than Zn(ll) to
histidine.
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2.3

EXPERIMENTAL SECTION

2.3.1

Materials and Methods.

Zinc(II) nitrate hexahydrate (>98% pure),

Iron(III) chloride hexahydrate (ACS reagent; >97% pure), Iron(Il) sulfate heptahydrate,
(>99% pure), Copper(ll) Chloride dihydrate (>99.99% disodium hydrogen phosphate
heptahydrate (Na2HP0 4,7H20) (>99.99%), sodium dihydrogen phosphate monohydrate
(NaH2P04 .H20) (>98%), L-Aspatiic acid (>98%), L-Giutamic acid (99%), L-Tyrosine
(>98%) were obtained from Aldrich and used as received. L-Histidine (>98% pure) was
obtained from Alfa Aesar. Deuterium oxide (Cambridge Isotope laboratories, Inc.) used
in NMR experiments had an isotopic purity of >99. 9% .
1

H NMR spectra (at 399.7MHz) were obtained on a Varian !nova 400

MHz spectrometer in D20 solutions at 25 °C. pH of the solutions was measured using a
Accumet excel XL15 pH meter.

2.3.2

Buffer Pt·eparations. A I 0 mM stock solution of the phosphate buffer

was prepared by dissolving the monobasic NaH 2P04.H 20 (0.0312 g) and the dibasic
Na2HP04,?H20 (0.2075 g) in distilled water (100 mL). pH of the buffer solution was
adjusted to 7.45±0.01 by titrating with concentrated hydrochloric acid solution, using the
pH meter.

2.3.3

NMR Titrations. A series of solutions of Zinc(II) nitrate in histidine

were prepared by adding appropriate amounts of Zn(N0 3)2 hexahydrate (0 to 53 mM in
D20) to histidine (92 mM in D20) so that the resulting solutions had Zn2+/His mol ratio
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varying from 0:1 to 6:1. Each of these solutions was buffered to pH 7.4 by adding 0.1 mL
of the buffer stock solution, and transferred into 5 mm NMR tubes. The 1H NMR spectra
of these solutions were recorded at 400 MHz at 25 °C. The stoichiometry of the metal
complexes was determined through linear least squares plots of changes in chemical
shifts (,A,.o) versus [Zn2+]/[His] from the abrupt changes in the slope.
The comparative binding efficiencies of Fe(III), Fe(II), Cu(II), and Zn(II) were
determined as follows: incremental amounts of Fe(III) (0 to 0.5 mol equivalents), Fe(II)
(0 to 0.1 mol equivalents) and Cu(II) (0 to 0.1 equivalents) salts were added to the 5 mm
NMR tubes containing solutions of Zn(II) and histidine in D 20 (mol ratio of
Zn(II):histidine = 0.5; initial concentration of histidine= 92 mM) and the spectra were
recorded at 25 °C. The NMR peaks gradually broadened and disappeared into baseline as
the concentrations of the salts increased. Similar titration experiments were carried out
for aspartic acid (40 mM), glutamic acid (50 mM). Due to limited solubility the NMR
experiments with tyrosine were done at much smaller concentrations (< 9 mM) and there
were no noticeable chemical shift changes under these conditions.
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3.

3.1

METAL ION BINDING STUDIES OF PEPTIDE MIMETICS AND
AMINO ACIDS

METAL ION BINDING STUDIES OF CARNOSINE AND HISTIDINE :
BIOLOGICALLY RELEVANT ANTIOXIDANTS.
3.1.1

Introduction. Age-related diseases including Parkinson disease and

Alzheimer's disease are characteristically associated with transition metal ion catalyzed
oxidative damage to lipids, proteins and nucleic acids. Transition metal ion catalyzed
lipid peroxidation, through Fenton reactions, leads to the formation of a variety of toxic
byproducts such as trans-4.hydroxy-2.nonenal (HNE) and trans-4.oxo-2.nonenal
(ONE).[ 32 ' 341The latter toxicants can potentially deplete intracellular levels of glutathione
and related cellular antioxidants. Biologically interesting antioxidants based on histidine
and its derived dipepides, and related analogues, play a major role in chelating transition
metal ions (Figure 3.1 )_PS-JJ!

Histidine

Carnosine (n = 1)
Homocarnosine (n = 2)

Figure 3.1. Structures of Histidine and carnosine.
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Further, they can exert their antioxidant properties through reaction with
secondary toxicants such a HNE and acrolein, thus attenuating their deleterious activities.
Histidine and its derivatives, in pmiicular, carnosine

(~-alanyl-1-histidine),

is also

postulated to be effective in trapping the Fenton reaction derived reactive oxygen species
(ROS). Carnosine is also known to be antiglycating agent as it can trap the advanced
glycation end products (AGEs) resulting from the Maillard reactions of protein amino
groups with reactive carbonyl compounds[JS-40J
Histidine-derived naturally occurring antioxidants such as carnosme and its
analogues, anserine and carcinine are known to be a superior in vivo antioxidant as
compared to histidine, although the precise mechanism of its antioxidant activity remains
to be established. [4 !-4SJ The antioxidants effects of histidine and its derivatives may be
ascribed to I) transition metal ion chelation, 2) trapping ofROS, 3) through reaction with
cellular toxicants such as HNE, and suppressing the formation of AGEs. [39• 49 l Chelation
of transition metal ions also helps in attenuating the production of ROS. It would thus be
interesting to explore whether, indeed, transition metal ion chelation play a major role in
the antioxidant propetiies of histidine and its derived peptides. The binding constants of
amino acids and peptides are dependent on the pH values of their corresponding
solutions. There have been reports of the binding constants of histidine and carnosine,
although a close comparison for these two compounds could not be achieved as they are
measured under varied experimental conditions. [Js-37• 42 ] With that goal, we have now
estimated the comparative binding constants of Cu(II) ions by histidine and carnosine at
close to physiological pH range under similar experimental conditions.
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3.1.2

Results and Discussion.

We have measured the binding constants of histidine

and carnosine with Cu(ll) ions in order to determine their relative metal ion chelating abilities in
aqueous solutions maintained at pH 7.84 ± 0.18, which is in the range of biological pH. We have
adopted the continuous variation method, as described by Karikari and coworkers, for the
measurement of binding constants.[50 ' 511 The relative volumes of the Cu(ll) solution and the
antioxidants are shown in (Table 3.1).

Table 3.1. Relative volumes of the stock solutions ofCu2+ and antioxidants, and the
resulting absorbances in the continuous variation method.

Volume

(mL)

of Volume

Cu(II) solution (2.00
X

10'2 M)

His/

(mL)

of Absorbance

Carnosine

solutions.

(2.00

X

Absorbance

(carnosine/ Cu2+ at (histidine/
800 nm)

at810nm)

10-2 M)
2.5

0

0.261

0.234

2

0.5

0.232

0.218

1.5

I

0.197

0.210

I

1.5

0.147

0.161

0.5

2

0.062

0.093

0

2.5

0.001

0.004

Cu2 +
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Thus the total volume of each of the solutions is kept constant at 2.5 mL, and the
sum of the moles of the Cu(II) and the antioxidant for each of these so lutions was also

o-5 moles), as required for the continuous variation method.

constant (5 x 1

The

absorption at 800 nm, for the Cu(II) species, was shifted to lower wavelengths upon
successive additions of the aliquots of the antioxidants, histidine and carnosine. The
absorption maxima for the complexed species were observed between 350 to 1000 nm
(Figure 3.2 and 3.3).
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Figure 3.2. UV/vis absorbance of L-Histidine-Cu(Il) complex
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Figure 3.3. UV/vis absorbance ofL-Carnosine-Cu(ll) complex

The absorbances at a fixed wavelength (800 mn in case of carnosine and 810 mn
in case of histidine) were then recorded at different mole fract ions (represented as X in
Figures 3.4 and 3. 5) of Cu(ll), and the changes in absorbance of the Cu(II) ion complexes
as compared to the uncomplexed Cu(Il) species were calculated from these spectra.
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Figure 3.4. Job's plot for L-Histidine-Cu(II) complex
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Figure 3.5. Job's plot for L-Carnosine-Cu(II) complex

From this data, JOB's plots were constructed which showed a 1:1 complexation
of Cu(II) for both histidine and carnosine. Thus, the plots involving Cu(II) mole fraction
versus the change in absorbance multiplied by the mole fraction of the substrates showed
parabolic curves in both cases.[SOJ These plots show a maximum at 0.5 mole fraction of
Cu(II) indicating their 1:1 complex formation with Cu(II) ions (Figures 3. 4 and 3. 5).
The binding constants (Ka) were estimated from the UV /vis spectral data using
Benesi-Hildebrand plots, involving plots of the inverse ofCu(II) chloride concentrations
against the

inverse of changes in their respective absorbances (1/L'lA vs 1/[Cu2+])

(Figure 3.6 and 3.7)[501 The following equation (1) was used to calculate the binding
constants from these plots:

L'lA

=

KaL'lA[ Cu]

I
L'lA

+-

(1)
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1
1
Where - -is the slope obtained from the Benesi-Hildebrand graph and - - is theyKaM
M
intercept. The binding constants of histidine and carnosine using the above procedure
were found to be 71.14 M- 1 and 1.1 M- 1, respectively.
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Figure 3.6. Benesi-Hildebrand plot for L-Histidine-Cu(II) complex
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At first glance it is intriguing that the Cu(II) ion binding constant of carnosine is
remarkably smaller than that of histidine. If metal ion chelation is the major factor in the
antioxidant effect of carnosine, we would have expected to obtain its superior Cu(II)
binding constant as compared to that of histidine. However, there are other mechanisms
of antioxidant effects, which include the sequestering of ROS, and removal of
intracellularly formed lipid-peroxidation derived toxicants such as HNE and acrolein.P 91
Products derived from the latter reaction pathway for histidine and carnosine have been
characterized by electrospray ionization mass spectroscopic techniques. l32 • 52 •53 1 It was
also suggested that among other mechanisms, carnosine may play an important role in
suppressing Alzheimer's disease through its ability to react with protein carbonyls and by
suppressing the reactivity of glycated proteins. [401 In accordance with our interpretation,
recently, Rizzarelli and coworkers have shown that Cu(Il) complexes of homocarnosine
are good scavengers of hydroxyl radicals, yet the complexation of Cu(II) is not
detrimental to the superior hydroxyl radical scavenging propetties ofuncomplexed
homocarnosine by itself. [S 4l
In conclusion, we have shown that carnosine has a relatively lower binding
constant with Cu(Il) ions as compared to that of histidine, which implies that the superior
antioxidant properties of carnosine may be attributed to other factors such as its efficient
trapping of ROS and sequestration of lipid-peroxide derived toxicants such as HNE.
However, transition metal ion chelation may be partly responsible for the antioxidant
behavior of histidine and its derivatives as they have significant metal ion binding
constants. Further experiments on the effect of pH and structural modifications of
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carnosine/histidine on the transition metal ion binding are currently in progress in our
laboratory.

3.1.3

Experimental Sections. Reagents and stock solutions: L-Histidine

(>98%) and CuCh·2HzOwere obtained fromAlfa, and !-carnosine (>99%) was obtained
fi'om Sigma Chemicals, and were used as received. A stock solution of the Cu(II)
chloride solution (2.00x I 0-2 M) was prepared by dissolving CuCh·H20 (0.178 g) in
distilledwater (SO mL),immediately prior to use. The 2.00x I 0-2M stock solutions of Lhistidine (0.155 gin SOmL H20; pH 7.71) and L-carnosine (0.225 gin SOmL H 2 0; pH
7.97) were prepared immediately prior to use.
Instrumentation: A Cary-50 UV/vis spectrophotometer equipped with a !em pathlength cell was used for the measurement of binding studies, and the spectra were
recorded in the range of350-IOOO nm. The micropipettes used were capable of
delivering lmL solutions, having adjustable ranges between I 00 and 1000

~tL.

Genera/methods for the determination of binding constants and stoichiometry of
complexation: A continuous variation method (or Job's method) was employed for the
investigations of the stoichiometry of the L-histidine- Cu(II) complex. Aliquots were
successively added to the cuvette accordingly as shown in Table I. The successive
UV/vis spectra are recorded from 350 to 1000 nm, and sample solutions showed UV/vis
absorbance in the range of0.02-0.30. The molar ratios of the two components were
varied, while maintaining the total volume in the cuvette at 2.5 mL. The UV/vis peaks
were shifted to lower wavelength regions, upon successive additions of the aliquots of
histidine or carnosine solutions. Changes in the relative absorption for each successive
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addition of the histidine or camosine multiplied by their respective mole li'actions were
plotted against the mole fraction of the Cu(II) chloride. These Job's plot resulted in
parabolic curves which show a maximum at 0.5 mol fraction of Cu(II) chloride indicating
1: 1 complex formation in both cases.

3.2

SYNTHESIS OF CYCLOPROPYL CONTAINING PEPTIDE MIMETICS

A variety of natural and synthetic cyclopropane containing compounds is known
to possess biological activity ranging from enzyme inhibitors, insecticides, antimicrobial,
antibacterial, antitumor to antiviral properties.[ 55 ' 63 l The biological activity of these
compounds can be attributed to unique reactivity due to unusual bonding and inherent
strain (27.5 kcal!mol), lipophilicity, and conformational restriction.[MJ As a rigid yet
chemically relatively stable structural unit, cyclopropane is smaller than isopropyl and
less sterically demanding than germinal dimethyl. Because of these characteristics,
cyclopropyl is being taken into consideration more and more in designing new
pharmaceuticals. The introduction of a cyclopropyl or its replacement of an alicyclic
chain or a larger alicyclic ring often showed beneficial effect to the bioactivity of the
original targets. We have synthesized histidine derived cyclopropyl containing peptide
mimetics (1.2) (Figure 3.8) and they were characterized using single X-ray
crystallography and Nuclear magnetic resonance spectroscopy. Metal ion binding
efficiencies of compounds 1 and 2 were estimated based on the chemical shift changes on
addition of copper (II) to a solution of these compounds in deuterated methanol.
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1

2

Figure 3.8 Structures of synthesized cyclopropyl derive peptide mimetics

3.2.1

Synthesis and Characterization. 1,2 deactivated cyclopropanes are

generally prepared by the condensation reaction of 1,2.dihaloethane and dialkylmalonate
using a base. Diethyl cyclopropane-!, l.dicarboxylate was first prepared by Perkin and
coworkers by heating diethylmalonate and 1,2.dibromoethane in the presence of
sodium ethoxide for 20h. The yield was only 29%. The disadvantage of this reaction is
the separation ofumeacted starting material dimethyl malonate and 1,2.dibromoethane
from the product by distillation. Later on the reaction conditions were varied by
researchers to get better yield.l 65 •741 All these reaction either gave poor yield or involved
harsh reaction conditions.l691 For example, using I, 2.dichloroethane, as an alternative to
1, 2.dibromoethane, resulted in the 50% byproduct tetraethyl butanel,l,4,4.tetracarboxylate, which is formed in a competing intermolecular reaction. Later
on potassium carbonate/dimethylfonnamide (DMF) was used as base instead of the
sodium ethoxide.l?SJ Carrying out the reaction at room temperature for 22h gave product
in 28% yield. [71) Phase transfer alkylation using potassium carbonate as a base and a
mixture of water and benzene as solvents significantly improved the yield to 85%. l661
The main disadvantages here were the longer reaction time (20 h) and high temperature
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(80 °C).Use of benzene is no longer allowed due to its carcengenicity. Klaus-Dieter
synthesized of 1,1-diactivated cyclopropane in 83% yield from 1,2-dichloroethane and
dimethylmalonate by heating the reaction to 115 °C in DMF.[?JJ Recently there was a
report on cycloalkylation reactions of active methylene compds. In the presence of
readily available imidazolium salts (ionic liqs.) as a phase transfer catalysts to afford the
dimethyl 1, 1-cyclopropanedicarboxylatel70l in 94% yield.
Our attempts to synthesize the dimethyl1,1.cyclopropanedicarboxylate following
reported literature procedures resulted in poor yield. We modified the procedure to
improve the yield and reduce the reaction time. Initially the 1, 2-dibromoethane was
reacted with dimethylmalonate in the presence potassium carbonate/DMSO at room
temperature for 24 Ius. The analysis of crude product by GC/MS showed 40% of
unreacted dimethylmalonate and 1,2-dibromoethane. Distillation of the product at low
pressure gave the pure product in 10% yield. The distillation was not very effective in
separating the starting compound. Most of the distillate contained a mixture of starting
compound and product.
Use of sodium hydroxide instead of potassium carbonate as a base, resulted in the
dicarboxylic acid derivative of cyclopropyl compound in low yield. We studied the
reaction in several solvents. The reaction was faster when DMSO was used as a solvent
may due to the higher acidity of diethylmalonate in DMSO. We varied the reaction
conditions for complete conversion of the starting compounds. Heating the reaction to
100 °C didnot afford a complete conversion even after 24 hrs.
Addition of phase transfer catalyst benzyltriethylammonium chloride to the same
reaction mixture also resulted in low yield and due to incompletion of reaction. Longer
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reaction time also didnot facilitate the completion of reaction. However, when the same
reaction was carried out in an ultrasonic bath, it was completed in 3hrs, in the absence of
a phase transfer catalyst (Scheme 3.1). This improvement of the reaction gave the product
in very high yield after extraction (80%). This is a very efficient method for the synthesis
of 1, 1-diactivated cyclopropyl compounds in high yield at a relatively shorter reaction
time and less harsh conditions.
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Br~Br

+

0
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K2C03,DMSO

/0~0"
0
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Ultrasonication, 3h

0
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I 00% conversion
Yield 85%
Br~Br

+
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0

3

4

K2C03, DMSO

0
RT -I 00°C, 24hrs

/0~0"
0

0
5

75% conversion
Yield I 0% after

distilation.

Scheme 3.1. Synthesis scheme for Dimethyl 1, 1-cyclopropanedicarboxylate.

The excess potassium carbonate and potassium bromide formed was simply
filtered and washed with DMSO to remove any product sticking to the solid.
Employment of DMSO as reaction solvent not only made the reaction faster, but also
made the extraction easier. Extraction of the product from the reaction mixture was
effected by freezing the reaction mixture to 0 °C. The DMSO (mp = 18.5 °C) solidifies at
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0 °C. The product was extracted using ethyl ether at 0 °C. Any residual DMSO is
removed by washing the ether solution with water. The product obtained was used
without further purification for the next step. Selective saponification of one of the ester
group was carried out by reacting stoichiometric amount of sodium hydroxide with
Dimethyl 1, 1. cyclopropanedicarboxylate in methanol/water solution (Scheme 3.2).

/0~0"
0

NaOH, Methanol

0

0

5

/o~o.H

RT, 12h

0
Sa

mp = 40°C

+

H.o~o.H
0

0

Sb
mp=137°C

Scheme 3.2. Saponification reaction of Dimethyl!, 1-cyclopropanedicarboxylate

The reaction yielded a 1:1 mixture of mono and dicarboxylic acid. These
compounds were separated based on their solubility in dichloromethane. Monocarboxylic
acid (Sa) was readily soluble in dichloromethane, where as dicarboxylic acid was almost
insoluble. The monocarboxylic acid has low melting point. It melted at 40 °C, where as
dicat·boxy lie acid melted at 13 7 °C. The compound S obtained was used without
purification for the next step. Compounds 1 and 2 were synthesized by coupling,
compound Sa, with histidine or histamine using reported literature procedure
(Scheme 3.3). 1761
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a

/O~O,H
0

0
5a

b

2

a Histidine/ EDCI/ dichloromethane/ water/ HOBt, triethylamine/; bHistamine/ EDCI/

dichloromethane/ water/ HOBt, triethylamine

Scheme 3.3. Synthesis scheme for cyclopropyl derived peptides.

The product obtained was extracted using ethyl acetate and purified by
recrystalization from hot ethylacetate. The compounds were characterized using NMR
spectroscopy and single X-ray crystallography. Compounds I and 2 readily gave X-ray
quality crystal from hot ethyl acetate solution .The single crystal X-ray quality crystals
were obtained by re-crystalization of the compounds I and 2 from hot ethylacetate
solution.
Compound I crystallizes in P2t2t2 1 space group and compound 2 in p2tlc. From
the X-ray crystal structure the molecule I can complex to metal ions through ring
nitrogen Nl and amide nitrogen N3 which will form a stable six membered ring. In the
case of compound 2, it can bind to metal ions through 02 and N3 (Figure 3.9).
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A

B

H10

Figure 3.9. Single crystal X-ray structure ofN-(a)-((1mehoxycarbonyl)cyclopropylcarbonyl)histamine (2) (B) and N -( a) -((1mehoxycarbonyl)cyclopropylcarbonyl)histidine ( 1) (A)

98

3.2.2

Metal Ion Binding Studies of Cyclopropyl-Derived Peptide Mimetics.

The metal ion binding efficiencies the compounds I and 2 were explored using 1H NMR
titration experiments. We selected Zn(II) for our studies, in order to avoid paramagnetic
broadening of peaks, which is evident in the case ofCu(II) and Fe(III) metal ions. On
addition of Zinc (II) nitrate to a solution ofN-(a)-((1mehoxycarbonyl)cyclopropylcarbonyl)histamine (or N-( a)-((1-Mehoxycarbonyl)
cyclopropylcarbonyl) Histidine), the absorption at 8 1H 7.5 corresponding to imidazole
2H and 8 1H 6. 7 corresponding to imidazole 5H shifted down filed and broadened (
refer to Figure 3.10 for numbering) . The absorption at 8 1H 7.5 was relatively most
deshielded indicating strong binding of N -(a)-( (1mehoxycarbonyl)cyclopropylcarbonyl)histamine( N -(a)-( ( 1-mehoxycarbonyl)
cyclopropylcarbonyl)histidine) through imidazole N3.

Figure 3.1 0. Structure ofN-( a)-((1-mehoxycarbonyl)cyclopropylcarbonyl)histidine

When 0.2 equivalents ofZn2+was added to the solution of N-(a)-((1mehoxycarbonyl)cyclopropylcarbonyl)histamine, the peaks at 8 7.5 and 8 6. 7 was shifted
to 8 7.9 and 8 6.9. The peak at 8 2.76 corresponding to C6H was also broadened and
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shifted downfield slightly (Figure 3.11 and Figure 3.12), indicating its proximity to
binding site.

Figure 3.ll. Structure of N -(a)-( (1-mehoxycarbonyl)cyclopropylcarbonyl)histamine
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Figure 3.13. 1H NMR titration of N-(a)-((1mehoxycarbonyl)cyclopropylcarbonyl)histidine (N-(a)-(( 1mehoxycarbonyl)cyclopropylcarbonyl)histidine) with Zn(II) in Methanol-d. Spectrum A
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[Zn(II)]/ [N-(a)-((1-mehoxycarbonyl)cyclopropylcarbonyl) histidine ratios are as
follows; B, 0.2; C, 0.5; D, 2.

101

C7 Hand cyclopropyl hydrogens are also broadened, but their chemical shift
changes were negligible. There was no further change in chemical shift on increasing
addition of Zinc (II) (up to 5 equivalents). Similarly on addition of0.2 equivalents ofZn
(II) solution to N-(a)-((1-mehoxycarbonyl)cyclopropylcarbonyl)histidine the peaks at 1i
7.5 and 1i 6.7 was shifted to 1i 7.9 and 1i 6.9 almost to the same extent as that ofN-(a)((1-mehoxycarbonyl) cyclopropylcarbonyl)histamine. Also the peak at 4.5 was shifted
downfield and broadened further confirming the main binding site as N3.Fm1her increase
in concentration of zinc nitrate (up to 2 equivalents), gave no chemical shift variations.
These results may indicate that compound 1 and 2 bind to metal ions at lower
concentration and higher concentration of the salt reduced the binding affinity.

3.2.3

Conclusion. Cyclopropyl-derived peptide mimetics (1 and 2) were

synthesized and characterized by NMR and single crystal X-ray crystallography. 1H NMR
titrations of these compounds with Zn(II) ions show that at low concentration, they bind
to metal ions and their main metal ion binding centre is N3 imidazole.

3.2.4

Experimental Section. Materials and methods. 1,2.dibromoethane

(>98%), dimethylmalonate (>98%), Zinc (II) nitrate hexahydrate (>98% pure),
potassium carbonate (anhydrous powder, >99.99%, dimethyl sulfoxide (Acs reagent,
99.99%), sodium hydroxide (Acs reagent, pellets, >99.99%), Methanol ( Acs reagent,
99.8%), N-(3 .Dimethylaminopropyl)-N '-ethylcarbodiimide hydrochloride (crystalline),
l.hydroxybenzotriazole hydrate (purum, >97%), Dichloromethane (Acs reagent, 99.5%)
and Triethylamine (>99%) were obtained from sigma Aldrich and used as received.
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Methanol-d (Cambridge Isotope laborotories, Inc.) used in NMR experiments had an
isotopic purity of>99.9%. 1H NMR spectra (at 399.7MHz) were obtained on a Varian
Inova 400 MHz spectrometer in methanol-d solutions at 25 °C (Figure 3.14 to Figure
3.18).
NMR Titrations. A series of solutions ofZinc(II) nitrate incompouns 1(2) were

prepared by adding appropriate amounts of Zn(N03)2 hexahydrate (0 to 200 mM in
methanol-d) toN-( a)-((1-mehoxycarbonyl)cyclopropylcarbonyl)histidine (42 mM
methanol-d) so that the resulting solutions had [N-(a)-((12
mehoxycarbonyl)cyclopropylcarbonyl)histidine ]/Zn + mol ratio varying from I :0 to 1 :5.
1

Each of these solutions was transferred into 5 mm NMR tubes. The H NMR spectra of
these solutions were recorded at 400 MHz at 25 °C . The metal ion binding efficiencies
of these compounds were determined from the chemical shift changes and peak
broadening.

3.2.4.1

Synthesis procedure: Synthesis of Cyc/opropane-1, 1-dicarboxy/ic

acid dimethyl ester (3): To Dimethyl malonate 1(10.5g, 79.5mmol) in DMSO (25mL)

added K2C0 3 (21.9g, 158.6mmol) and I, 2.dibromoethane 2(15g, 187.86) respectively.
Reaction was then heated in ultrasonic bath 3 h. Completion of reaction was checked by
GC/MS.The reaction mixture was filtered and precipitate was washed with ether
(IOOML) to remove solid potassium carbonate and potassium bromide .The filtrate was
frozen to 0 °C. The solid DMSO formed was removed by decanting the liquid at 0 °C.
The melting point of the DMSO is 18.5 °C. The ether layer was washed with water was
dried over anhydrous sodium sulfite. Concentration of ether solution in rotary evaporator
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and high vacuum gave the product as a clear liquid (80%, lOg). El/MS, IS7, 127, 9S, 68;

1H 1i CDCb: 3.7 (bs, 6H) 1.3 (bs, 4H); 13 C 1i CDCb: 171.1, S2.8 (q, Jc.H= 146Hz),
28.6, 16.3 (t, Jc.H= 171Hz)

Synthesis ofC),clopropane-J,J.dicarboxylic acid methyl ester (5a): To Dimethyl
I, 1-cyclopropanedicarboxylate (7.2g, 4S mmol ) dissolved in methanol (1 0 mL) , sodium
hydroxide (1.82g, 4Smmol )dissolved in 10 mL of water was added at 0 °C slowly .The
reaction was stirred at room temperature for 12hrs and completion of reaction was
checked with GC/MS. The reaction mixture was washed with pentane at a pH of7 to
remove any statiing material and excess methanol was removed under high pressure. The
concentrated solution is acidified to pH 3 and transferred in to separatory funnel and
extracted with ethyl acetate. Ethyl acetate solution is concentrated to obtain a I: I ratio of
mono and dicarboxylic acid as crystalline solids, which melts at room temperature as
shown by NMR. Two compounds were separated based on difference in solubility in
dichloromethane. Compound Sa is extracted from the mixture by repeatedly washing with
dichloromethane. Compound Sb was left as a solid. The dichloromethane solution was
filtered and filtrate is concentrated and refrigerated to obtain Sa as crystalline solid (mp
40 °C). Total Yield was 88%.; 1H 1i methanol-d: 3.6 (bs,3H) 1.7-1.6 (m, 4H);

13

C

1i methanol-d: 174.S, 171.7, S3.0 ( quatiet, J = 147 l-Iz), 2S.6, 20.6 (t, J= 169Hz); The
solid left after washing with dichloromethane was dried to obtain Sb (mp 137 °C) . 1H

1i methanol-d: 1.4(bs, 4H);

13

C 1i methanol-d: 177, 2S.7, 20.8 (t, J = 169Hz).

Procedure A: Synthesis ofN-(a)-((1-Mehoxycarbonyl)
cyclopropylcarbonyl)histidine (1). In an RB flask, compound 4(1.0 g, 6.8 mmol),
Histidine methylester dihydrochloride (1.6g, 6.8 mmol), N-methylmorpholin( 2.0g, 20.4
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mmol), EDC hydrochloride (1.3g, 6.8 mmol), and l.hydroxytriazole ( l.lg, 6.8 mmol)
were dissolved in dichloromethane/water (SmL/SmL) solution and stirred for 12 hrs. The
reaction mixture was extracted with dichloromethane and washed with water. The
dichloromethane solution was dried using MgS04 and concentrated in a rotary evaporator
to obtain compound 1 as white precipitate. Solid obtained was purified by recrystalization
form hot ethyl acetate solution. Yield 15%. Decomposed on heating to 200 °C; 1H NMR
(400 MHz, Methanol-d) 8 7.45 (s, !H), 6.75 (s, !H), 4.55 (dd, 2H, J =15Hz), 3.55 (s,
3H), 2.95 (m, !H), 1.35 (m, 4H);

13

C NMR (1 00 MHz, CDCb) 8 173.5, 171.8, 169.0,

135.7, 133.4, 117.2, 53.0, 52.2, 29.9, 26.4, 20.4.

Synthesis ofN-(a)-((1-Mehoxycarbony/) cyclopropylcarbonyl)histamine (2): The
compound 2 was synthesized following the procedure A. White crystalline solid (yield
20%); mp = 130 °C, 1H NMR (400 MHz, Methanol-d) 8 7.56(s, !H), 6.86(s, !H), 3.64(s,
3H), 3.47(t, 2H, J =8Hz) 2.76(t, 2H, J= 8Hz), 1.46 (m, 4H);

13

C NMR (100 MHz,

Methanol-d) 8 174.2, 170.5, 136.1, 117.7, 52.8, 40.6, 27.7, 27.6, 19.0.
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3.2.4.2 Single crystal X-ray crystallographic analysis.

CIJIS/al Structure

Analysis of compound 1: Data collection: Bruker Instrument Service v2009, 3, 0, 0; cell

refinement: APEX2 v2009.3 .0 (Bruker AXS); data reduction: SAiNT V7.60A (Bruker
AXS , 2008); program(s) used to solve structure: SHELXS97 (She ldrick, 2008);
program(s) used to refine structure: SHELXL97 (Sheldrick, 2008).

II 0

Table 3-2. Crystal data for compound I

c,,H,sN303

F(OOO) = 504

M,=237.26

D, = 1.370 Mg m·3

Monoclinic, P2dc

Mo Ka radiation, A= 0.71073 A

Hall symbol: -P 2ybc

Cell

parameters

from
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reflections

a= 10.2579 (5) A

8 = 2.9-28.1"

b = 9.3388 (5) A

~~ = 0.10 mm·'

c = 12.2079 (5) A

T= 154 K

~

Cut fragment, clear colourless

= 100.466 (1) 0

V= 1150.02 (10) A3
Z=4

0.46 x 0.41 x 0.40 mm
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4. BORON BASED ANION RECEPTORS: SYNTHESIS, ANION
BINDING STUDIES, AND AB-INITIO CALCULATIONS.

4.1 INTRODUCTION
A large number of boron based anion receptors have been developed to
selectively bind fluoride ions.P-21 Among the biologically important anions, fluoride
anion has received much attention due to its established importance in preventing dental
caries. Fluoride is also an important constituent of osteoporosis drugs. Regardless of the
beneficial advantages, overdoses of fluoride results in dental and skeletal fluorosis.
Further, fluoride ion receptors have major applications in lithium ion batteries. Lithium
fluoride being a low molecular weight salt potentially impmts high power densities to
lithium ion batteries. However, due to its insolubility in commonly used carbonate based
electrolyte solvents, its application in lithium ion batteries are limited. Appropriate anion
receptors would help dissociate lithium fluoride and increase its solubility.

[3-

41

Anions are Lewis bases, which can interact with Lewis acidic species. Tricoordinated boron compounds can bind anions covalently to form complexes. On
2
complexation with the anions the hybridization of boron changes partially from sp to sp3.
Compared to pure Columbic interaction which depends on the distance and size of the
charge, Lewis acid base interaction depends on the properties of the interacting species.
e.g, stereo electronic properties, symmetry of molecular orbitals, hard-soft property, back
bonding ability etc.1 2· 51
The chemistry of boron-based anion receptors stmted when Shriver and Biallas 161
first reported the anion chelating ability of acyclic boron compounds in 1967. Shriver and
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coworkers showed that bis(difluoroboryl)ethane I can chelate methoxide ions.1 61 In a
competition experiment they found that the complex formed by bidentate ligand is more
stable than the monodentate ligand BF3 (Scheme 4.1).
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Scheme 4.1. Chelated complexes of bis(difluoroboryl)ethane.

In 1985 H.E. Katz[7-SJ synthesized 'hydride sponges' which was a naphthalene
derivative of bisdimethylborane 6 (Figure 4.1). In solution the compound was able to
abstract proton from potassium hydrides and other borohydrides. The X-ray crystal
structure of the complex 6 with KH showed that hydride is unsymmetrically bound
between two boron atoms with an average 8-H-B bond length of 1.3 A 0 (1.20 and
1.49A0) and an angle of 140°.

119

Compound 6 was able to abstract proton from compound 5 indicating that chelate
effect stabilizes the complexes. These compounds were shown to complex fluoride ions
and hydroxide ions. In 1987 same author synthesized naphthalene derivative of
bis(dichloroborane) which was the first bidentate boron chloride chelate (8).l91 X-ray
crystallography showed that chloride is chetaled by two boron atoms symmetrically with
B-Cl bond length of 1.83 A 0 (Figure4.1).
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Figure 4.1. Naphthalene derived bidentate Lewis Acids for fluoride anion receptors.
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Scheme 4.2. Perfluorinated aryl derived diboranes complexe with fluoride, hydroxide,
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William and coworkers showed that perfluorinated aryl boranes(9) complexes
with fluoride, hydroxide, chloride and methoxide ions. The anions are chelated between
the boron atoms which are 3.13 A 0 apart1101 (Scheme 4.2).Boron based bidentate,
colorimetric and phosphorescent fluoride sensors have also been repotted Compound 11,
for example, originally yellow in color, upon complexation with fluoride becomes
colorless.P 11 The mercuriated analog of the latter compound 13 on the other hand gives
phosphorescent fluoride adducts (Scheme 4.3).1 121
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Scheme 4.3. Examples ofbidentate Lewis acids as Colorimetric and Phosphorescent
Fluoride Sensor.

All of these bidentate anion receptors for fluoride, as discussed above are limited
to organic solvents. Due to the importance of detection of fluoride ions in water, Hudnall
and coworkers developed cationic boranes, involving quaternary ammonium and
phosphonium groups (15, 16 and 17) for fluoride anion binding in aqueous solutions
(Figure 4.2). [121 However, their binding constants with fluoride are less than their related
bidentate anion receptors. More importantly, compounds 15 and 17 are selective for
fluoride anion, whereas para-substituted compound 16 is relatively more selective for
cyanide anions.
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These differences in their relative binding constants may be explained as due to
the enhanced electrophilicity of the boron center when the electron withdrawing
quaternary ammonium group is in the arrha-position. Fluoride anion, being hydrated in
the aqueous solution, is relatively less nucleophilic than the cyanide and hence the
increased electrophilicity is required for its binding. The relatively more bulky cyanide
anion, on the other hand prefers the para substituted receptor, 16. In other words, the
boron center in compound 16 is not sufficiently electrophilic for the fluoride anion
binding.

Mes

Mes

"/ ke
B

Ph

M

O

.._Ph

..-9

16

15

17

Figure 4.2 Examples of boron based anion receptors for selective binding of
fluoride ions and cyanide ions from water.

In addition to boron,

mercury, tin and silicon derivatives, e.g., compounds 18,

19, and 20 have also been reported as

anion receptors (Figure 4.3).

anion receptors are not useful as selective fluoride anion receptors.

[IZJ

However, these
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Figure 4.3 Other Lewis acid based receptors.

Anions are always accompanied by their counter cations. Therefore, one approach
to synthesis of anion receptors is to synthesize dual ion receptors which are capable of
binding both anions and cations, which increases the stability of the fluoride complexes.
Very few Lewis acid based ditopic anion receptors, such as crown ether derived
boronates (e.g., 21) are reported to date. 1' 21 Compound 21 binds to potassium fluoride
more efficiently as compared to related boron derived anion receptors lacking the crown
ether substituent (Scheme 4.4). Crown ether moiety in compound 21 selectively binds to
K+ and the boron binds to the fluoride anion giving the ditopic complex 22(Scheme 4.4).

KF

21

22

Scheme 4.4. Ditopic anion receptors.
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4.2 SYNTHESIS AND FLUORIDE ANION BINDING STUDIES OF BORANE
BASED ANION RECEPTORS
4.2.1

Introduction. Boranes are Lewis acidic compounds which can bind to

nucleophilic anions. Previous studies as discussed above had shown that Lewis acidic
boron center is a selective binding site for fluoride ions presumably due to hard acid-base
type interaction. The binding affinity of boron center can be fine tuned by the electronic
effects of substituents at the boron centre. Towards this goal, we have synthesized
fluorinated borane based anion receptors (Figure 4.4), and their binding affinities with
various anions were studied using multinuclear NMR, UV-Vis and mass spectroscopy.

0

0

OACFJ

FJCA0/~'-.0
F3CAO
Bron trifluroacetate
(BTIA)

Figure 4.4. Structures ofBTTA and B (0Tf) 3

4.2.2

Synthesis and Fluoride Ion Binding Studies of Boron Tris(tl'ifate).

Boron tris(triflate) was synthesized using reported procedures(Scheme 4.5).Il 31 Boron
tribromide was reacted with triflic acid at 0 °C under inert atmosphere. A white
precipitate was formed which was filtered under ine1i atmosphere and dried under high
vacuum overnight to remove the hydrogen bromide produced.
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Scheme 4.5. Synthesis of Boron tris(triflate) (B(OTf))

NMR analysis of the B(OTf)3 showed that it forms adducts with solvents such as
dimethyl sulfoxide (Figure 4.5) and acetonitrile (Figure 4.6). Triaryl boranes are known
to form solvent ad ducts with acetonitrile. [1 4]
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In acetonitrile solution three

19

F peaks peaks were observed at -78.55 (B), -78.39

(C) and -78.09 (D) ppm (Figure 4 .7). In order to investigate whether any of the peaks

correspond to triflic acid, increasing amount of triflic acid (100 pL) was added to the
solution of boron tris(triflate) in acetonitrile . On addition of triflic acid a new peak
emerged at -77.7 ppm corresponding to triflic acid which was verified by adding extra
amounts of triflic acid (Figure 4.6). The unidentified peaks may correspond to solvent
adducts of Boron tris(triflate). Thus boron tris(triflate)

is not a suitable candidate for

stduying fluoride ion binding due to its moisture sensitivity and reactivity with solvents.
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4.2.3 Synthesis and fluoride ion binding studies of Boron
tris(trifluoroacetate). Boron tris(trifluoroacetate) was synthesized by slight
modification of the reported procedure by Pless and coworkers (Scheme 4.6)_11 51To
boron tribromide in an RB flask under ine1i atmosphere, at 0 °C trifluoroacetic acid was
added dropwise. Immediately on mixing of the two reagents a white precipitate was
formed which was washed with dichloromethane (DCM) 2.3 times (20mL). Removal of
any residual solvent in high vacuum gave a white precipitate in 95 % yield. NMR
analysis of these compounds in various solvents such as acetonitrile, dimethyl sulfoxide
showed that it reacts with solvents (Figure 4.7). Due to its intrinsic Lewis acidity it may
be forming adducts with nucleophilic solvents.

0

° C, < 5 min., N2

Scheme 4.6. Synthesis of Boron tris(trifluoroacetate)

In acetonitrile (Figure 4.7) larger peaks at
smaller peaks at

o76.2

and

o 75.5

o 75.8

corresponds to BTTA and

corresponds to solvent adducts with acetonitrile.
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Similarly with DMSO there were tlU'ee larger peaks at 8 75.1, 75.4 and 75.5 (Figure 4.7).
Due to its intrinsic Lewis acidity it may be forming adducts with nucleophilic solvents. It
was also found that BTTA polymerizes THF solvent in accordance with the literature
reports.[' 6l
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F NMR ofBTTA in acetonitrile (left) and dimethylsulfoxide(right).

In order to determine the fluoride ion binding affinity, BTTA was titrated with,
tetrabutyl ammonium fluoride (1.2 equivalents) in acetonitrile and DMSO (Scheme 4.7).
NMR analysis of the resultant solution shows that on addition of fluoride ion additional
peaks were formed in the range of 8 -75.62 to -76.32ppm in acetonitrile and other
solvents. UV-Vis spectroscopic titrations also indicated the formation of multiple
equilibria. Thus BTTA is not a suitable compound for fluoride ion binding studies using
NMR or UV spectroscopy.
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BTTA

BITA-Fluoride

Scheme 4.7. Fluoride ion binding ofBorontris(triflate)

4.3

SYNTHESIS AND ANION BINDING STUDIES OF BOROXIN-BASED ANION
RECEPTORS.

Boroxines are cyclic trim eric esters of boronic acids. Although boroxin-based
polymers have been used as flame retardants and as electrolytes in lithium ion batteries.
[l?-ISJ

they were never explored as anion receptors. It is well known that they coordinate

with N-containing ligandsY 91

20 221
[ -

Here we disclose our results on the effect of

fluorinated boroxines, tris(2,6-difluorophenyl)boroxin (DF; 23),
tris(2,4,6)trifluorophenylboroxin (TF; 24), and tris(pentafluorophenyl)boroxin (PF; 25)
as novel anion receptors for potential applications in lithium ion batteries, through abinitio theory, fluoride anion binding studies( Figure 4.8). These cyclic fluorinated

boroxines have additional advantages as their Lewis acidity could be readily modulated
by varying the number of fluorines on the aromatic rings. Our density functional theory
(DFT) calculations substantiate this hypothesis and serves as a predictive tool for
identifying the optimal anion receptors.

130

F*F F
F --'

A
FfF

I~

F

F*:~:::~*: F

~:::~n:
1_.,

F
F

F F

I_.,

F
F

Tris( 2,6 -difluorophenyl) boroxin Tris(2, 4, 6-trifluorophenyl) Boroxin (TF)

I.,;

F F

F

F

F

Tris(pentafluorophenyl) Boroxin (!'F)

(DF)

24

23

25

Figure 4.8: Structures of fluorinated boroxines.

4.3.1

Results and Discussions. Boron-based anion receptors such as

tris(pentafluorophenyl)borane have recently been used for selective binding of fluoride
anions in lithium ion batteries. 123 -261 In order to systematically fine tune the binding
efficiencies of the boron based anion receptors, we have now synthesized a series of
fluorinated arylboroxines- DF (23), TF (24), and PF (25)- by thermal dehydrative
cyclizations of the corresponding arylboronic acids. The structures of these compounds
were readiy assigned based on 19F- and 11 B NMR spectra, which closely match with
those calculated by ab-initio theory.

11

B NMR are especially diagnostic of the structures

as deviations of the experimental chemical shifts from GIAO/B3LYP-6-31 G** derived
values are of too small:

L'.o =

1.7 (DF), 0.2 (TF), 0.5 (PF).

The synthetic method adapted is comparatively simple and allows synthesis of a
wide variety of fluorinated boroxines from their corresonding arylboronic acids (Scheme
4.8). 127-291 Further, the binding efficiencies of these boroxines can be readily optimized
by tailoring the degree of fluorination on the aryl rings, or by incorporating additional
electron-withdrawing groups. These anion receptors could be readily monitored for their

I3 I

anion binding efficiency using 19F and

11

B NMR spectroscopy. We have explored

fluoride anion binding efficiencies, and binding stoichiometries of these boroxines.
These results are further substantiated by ab-initio theoretical calculations.

(I)

Heat
-H20

DF (23); TF (24); PF (25)

Scheme 4.8. Synthesis of fluorinated boroxines.

4.3.2
by 19F and

11

Structural Characterization. The boroxines 23.25 were characterized
B NMR spectroscopy and the structures were confirmed through comparison

of the chemical shifts with those obtained by

ab-initfo GIAO/B3L YP/6-310**' 301

method (Figure 4.9). The 19F NMR spectrum for DF (23) showed a single absorption atI 03.0 ppm which is very close to the GIAO/B3L YP/6-31 G**
(24) showed two

19

of -I 01.7

(~8 =

1.3). TF

19

F absorptions at 8 F -99.9 (ortho-F), and -106.8 (para-F), agreeing

with those ofDFT-GIAO calculations: -104.8 (ortho-F, M

=

4.82), -105.5 (para-F,

~8 =

2.34). PF (25) showed three absorptions at -132.4 (ortho-F), -153.7 (para-F), and -163.0

(meta-F). The ortho-, meta- and para- fluorine assignments are suppmied by the abinitio calculated chemical shifts, although the theoretically obtained chemical shifts are
deviating from the experimental values by 6 to 10 ppm. Fmiher, the

11

B NMR spectra

132

closely match the experimental values for DF (118 = 1.7), TF (118 = 0.2) and PF (118 = 0.5)
showing that the GIAO

11

B NMR chemical shifts are reliable indicators of the structural

characterization of the boroxines.l31 -321
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Figure 4.9. Experimental (acetonitrile solvent; in parenthesis) and GIAO/B3LYP/6310** calculated 1i 19 F (liCFCh = 0) and 11 B NMR spectra for DF, TF and PF; DF; 1i 11 B
are shown using arrows (1iBF3.0Et2 = 0).

Further, structures of these compounds are confirmed by electron impact
ionization mass spectroscopic (EI/MS) studies. A solid probe technique was used for
mass spectroscopic studies. The compound was loaded in to solid probe and subjected to
electron impact ionization. The EI mass spectrum ofDF, TF and PF gave abundant
molecular ion peaks indicating that molecular ions are stable under mass spectroscopic
conditions. Isotopic abundance measurement confirmed the assignment of molecular ion
peaks. EI analysis showed the molecular ion peaks for DF, TF, and PF, at m/z 420,474
and 581 respectively (Figure 4.10).
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Figure 4.1 0. EI/MS spectrum of DF recorded at 70eV showing molecular ions and
daughter ions.

Mass spectrum of DF showed 5 daughter ions with appreciable abundance at 326,
42, 140, 94, and 75 (Figure 4.10). These m/z values could be readily assigned to
fragments 23a, 23b, 23c, 23d and 23e as shown in Scheme 4.9. Loss of fluorobenzyne
radical C6 H3F

fi·om molecular ion (m/z 420) gives a fragment at m/z 326 with 26 %

abundance relative to molecular ion peak. This fragment is formed by cleavage of boron
aryl bond and migration of orthofluorine on phenyl ring to boron centre.
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Scheme 4.9. The proposed fragmentation mechanism of DF in EI/MS.

The fragmentation pattern is repeated further. The loss of2 fluorobenzyne
radicals (a loss of C 12 H6 F2 ) lead to the formation of fragment at m/z 42 with an
abundance of 36%. The peaks at m/z 140 arise by B-0 cleavage with an abundance of
29%. The low abundance of these peaks shows the relative thermal stability ofboroxines.
The relatively intense peak (an abundance of79%) at m/z 94 is assumed to be due to a
fluoorobenzyne radical which was the most abundant daughter ion in the spectrum. It
further underwent the cleavage C-F bond to give a fragment at m/z 75(30%), which is
probably due to benzyne radical cation, which is unprecedented. The assignments of
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peaks are further confirmed by the comparing observed and calculated isotopic pattern
(Table 4.1 ). The peaks at m/z 420, 326 and 42 showed an isotopic pattern corresponding
to B3. The M-2, M-1, M, M+ I peak are well within the range calculated.

Table 4.1. Isotopic pattern of molecular ions and selected daughter ions ofDF.

418

15.0

16.3

324

6.0

17.0

230

21.3

17.7

419

59.2

67.9

325

70.4

69.9

231

74.1

72.1

420

100.0

100.0

326

100.0

100.0

232

100.0

100.0

421

21.7

18.7

327

12.5

12.9

233

9.6

6.9

422

2.6

2.3

328

1.4

1.4

234

6.2

0.8

In some cases the slight difference is from the peaks over lapping due to the loss
of proton form the fragments. The fragment at 140 showed an isotopic pattern
corresponding to B1. Similarly EVMS spectrum ofTF showed major peaks at m/z 474,
362, 60, 158 and 112.The base peak was molecular ion peaks at m/z 474. Formation of
daughter ions can be easily explained using the same mechanism as in the case of DF.
The assignments of the peaks are further confirmed by isotopic pattern calculation.
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In the case ofPF the major peaks were at m/z 581,434,286, 194, 148. PF also
followed the same fragmentation pattern as DF and TF. The fragmentation pattern shows
the possible involvement of a 1,3.sigmatropic migration of the ortho-fluorine from the
aryl rings to boron in concert with elimination of corresponding fluorobenzyne (Scheme
4.9), which will be discussed later in this section. A similar mechanism was shown by the
fluoride adducts ofDF, TF and PF (vide infi'a) in ESI!MS studies.

4.3.3

Solvation effect.

It has been established through X-ray diffraction

studies that tris(pentafluorophenylborane) can form 1:1 adducts with solvents such as
acetonitrile. 133 1 In order to see similar solvation effects on fluorinated boroxines, we have
19
explored the effect of solvents on the stabilization of the boron centers through F NMR

spectroscopy (Figure 4.11, Figure 4.12 and Figure 4.13) In the relatively non
19

nucleophilic solvent, dichloromethane DF shows a single absorption at 8 F -104.5,
whereas in acetonitrile, dimethylsulfoxide, and ethyl acetate, the absorption has shifted to
downfield by 1 ppm to -103. It shows significant solvation effect from these solvents.
Similarly, for TF 8 19F(CH2 Ch) signals at -10l.l(ortho-F) and -103.2 (para-F) are shifted
downfield by I ppm for the ortho-fluorine, and para-fluorine is shifted by 4 ppm upfield
in DMSO, acetonitrile and ethyl acetate.
On the other hand, PF (6) shows relatively more sensitivity to solvation effects. In
the more coordinating DMSO solvent, the 8 19 F (CH2 Ch) signals at -132.8 (ortho-F),149.6 (para-F), =161.5 (meta-F) are split into multiple peaks from -131 to -164 ppm in
DMSO indicating the formation of stable PF-DMSO adducts. In acetonitrile and ethyl
acetate solvents, the 8 19F(CH2 Ch) absorptions are shifted downfield by 0.5 ppm for

137

ortho-fluorines, upfield by 5 ppm for para-fluorines, and upfield by 2 ppm for the metafluorines.
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Figure 4. 11 .

The

F NMR spectra of DF (4) in CH3CN (A), EtOAc (B), DMSO (C), and
CH2Ch

19

F NMR of'PF, TF and DF in various solvents thus clearly show the

importance of solvation. In case of TF and DF there is rapid exchange of the solvent
molecules among the tlu-ee boron centers of the complex so that only a single

19

F NMR

absorption is observed for the all the aromatic ortho or para fluorines . However, in
relatively more polar DMSO solvent, add itional distinct absorptions for PF-DMSO
adducts could be observed. This indicates relatively slovv exchange of the DMSO with
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PF. Unlike the starting boroxines, the boroxin-fluoride adducts (in the presence of excess
fluoride anion) have similar

o19F

in all the solvents studied (CH2Ch, acetonitrile, and

DMSO), showing that the solvent participation is minimal in the case of the fluoride
adducts.
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Figure 4.12.
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F NMR spectra of TF (5) in CH3 CN (A), EtOAc (B), DMSO (C), and
CI-hCh
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4.3.4

19

F NMR spectra of PF (6) in CH3CN (A), EtOAc (B), DMSO (C), and
CH2Ch

Fluoride Anion Binding.

Fluoride anion binding to anion receptors

helps not only the solubility of the otherwise insoluble lithium fluoride electrolyte in
nonaqueous organic solvents, but also dramatically increases the lithium ion
conductivities. Reversibility of fluoride anion binding is crucial in the next generation
dual ion intercalating lithium ion batteries. In order to understand the structural effects
on the fluoride binding to anion receptors we carried out DFT calculations on a series of
fluorinated boroxines, and the results are shown in Table 4.2 and Figure 4.14. As can be
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seen from (Figure 4.14) fluoride anion binding is correlated with the number of the
fluorines on the aryl rings: the more the number of fluorines in the aryl rings, the higher
the binding efficiency of the boronic anhydrides (boroxines). Because there is more than
one boron capable of anion capture we estimated the binding energies for the second and
third fluoride and report the data in Table 4.2. These calculations are less reliable because
they involved highly charged species. Nonetheless it appears than multiple bindings are
favorable (exothermic). Second and third anion binding energies do not follow the same
trend as a function of fluorination that the first anion binding follows.
To understand the binding abilities of the fluorinated boroxines with fluoride
anion we have carried out 19 F NMR spectroscopic studies for solutions of boroxines with
varied amounts of TBAF. A series of samples of boroxines (23 .25) were prepared in
acetonitrile, dichloromethane, and DMSO, containing 0, I, 2, and 3 equivalents of
TBAF and CFCb (liCFCb

=

0) as the internal reference, and the spectra were recorded in

the unlocked mode. The 19F and

11

B NMR spectra of the boroxin-fluoride complexes (26-

28) in acetonitrile are summarized in Figure 4.16 and Figure 4.17 respectively. OF19

Fluoride complex, 26 (with two equivalents ofTBAF), shows a single absorption, li F110.4 (ortho-F). TF-fluoride complex, 27 (with two equivalents ofTBAF), also shows
only a single

19

F absorption at -107.9 ppm, due to the coincidental merging of the ortho-

and para- fluorines; i.e., the ortho- fluorines are shielded much fatiher than the parafluorine, with respect to the corresponding neutral boroxin. PF-fluoride complex, 28
(with one or two equivalents ofTBAF), shows three
-155.3 (meta-F), -162.9 (para-F).

19

F absorptions at -139.3 (ortho-F),
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Table 4.2. Fluoride (F) anion binding energies (B3LYP, LACVP**), solvation energies
and degree of fluorination for various fluorinated arylboroxines.

Degree of
Fluorination

Binding
Energy(Kcal/mol)

tris(pentajluorophenyl) boroxin (2 5)

15

74.1

(2, 6-dijluorophenyl)-bis(pell/ajluorophenyl*)boroxin

12

73.1

bis (2, 6-dijluoropheny!)-(pentajluorop heny !*)boraxin

9

71.0

bis(2,6-dijluorophell)'l*)-(pentcifllwrophenyl)boroxill

9

70.0

Iris (2, 4, 6-trijluorophenyl) borax in (2 4)

9

69.3

tris(2,6-dijluorophenyl)boroxin (23)

6

67.5

tr is (4 jluoroph eny!) boroxin

3

61.6

(2, 6-dijluorophenyl)-bis(pentcifluoropheny!**)bol·oxin

13

49.1

bis (2, 6-dijluoropheny/ *)-(pentcifluorophenyl *)borax in

10

45.9

Compound

Second Anion Captured
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Fluorinated phenyl boroxines
First Fluoride Binding Energtes
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Figure 4.14. Effect of degree of aryl fluorination on the fluoride anion binding energies
of arylboroxines from DFT (B3LYP).

The assignments of the chemical shifts of these boroxin-fluoride complexes, 26,
27, and 28, could be readily confirmed through their DFT-GIAO chemical shifts (Figure
4.15). The DFT-GIAO derived 8 19F for the ortho- fluorines in these complexes vary
slightly from each other, whereas they show single absorptions in solution NMR,
indicating rapid rotation across the B-aryl bonds in the solution phase. Further, the DFT
values also reflect different chemical environments for the two sets of aryl groups. In
solution, due to the rapid intramolecular exchange of the fluoride anion among the three
borons, a single 8 19F absorption is observed (vide infi'a). The DFT-GIAO predicts a 8 19F
of -166.7, -168.8, and -164.6 for the B-F fluorine in structures 26, 27, and 28,
respectively. These absorptions could not be observed in solution, perhaps due to the
rapid intramolecular fluoride anion exchange (vide infi'a).
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Upon addition of I mol equivalent of TBAF to PF (25), in acetonitrile solvent,
complete disappearance of the 19 F NMR peaks for the starting material was observed, and
a three line 19F NMR spectrum for PF-fluoride complex, 28, was observed: o19 F -139.3, 155.3,-162.9 (Figure 4.16). However, for DF (23) and TF (24), upon addition of one
mol equivalent ofTBAF, a complex spectrum resulted with multiple absorptions
conesponding to the boroxin-fluoride complexes (26 and 27), presumably because of
their equilibration with unreacted boroxines. Addition of two mol equivalents ofTBAF to
these solutions resulted in surprisingly simplified spectra showing only one absorption
(less than 0.1% of starting material could be observed by 19 F NMR).
These results show that PF has relatively stronger fluoride affinity as compared
to those of DF and TF. The data in (Table 4.2) is also in accordance with these results;
i.e., the higher the aryl-fluorination the stronger the fluoride binding. At first glance we
would have expected distinct 19 F absorptions for the two sets of aromatic rings for
complexes 26-28; i.e., the aryl rings bound to sp3·hybridized boron are chemically
different than those attached to sp 2 hybridized boron. The observation of a single ortho19F (or para- 19 F) absoption for each of these complexes (with excess fluoride in case of
DF and TF) shows that there is a rapid intramolecular fluoride exchange between the
three borons (equation 2) with an upper limit offree energy of activation of 12.5, 12.4,
and 12.0 kcallmol for boroxin-fluoride compexes 26, 27, and 28 respectively
(corresonding to exchange rate constants of 4400 s· 1, 4800 s- 1 and 9200 s- 1,
respectively).l 341 Presumably due to this low barrier for exchange the o19 F for B-F
fluorine could not be observed in solution (vide supra).
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Figure 4.15. Experimental (acetonitrile solvent; 8 F in parenthesis) and
GIAO/B3L YP/6-310** calculated 8 19F (8CFCh = 0) for the boroxin-fluoride complexes
(26-28); 8 11 8 are shown using arrows (8BF3 0Et2 = 0).

Anion receptor PF (6), in acetonitrile, in the presence of 1 mol equivalent of
fluoride, showed three new absorptions at -139.3 (ortho-F), -155.3 (para-F), -162.9
(meta-F) corresponding to the PF-fluoride complex, and the absorptions for PF have

completely disappeared (Figure 4.16). Further addition ofTBAF (2 to 3 mol equivalents)
resulted in no change of the spectra, showing that the stoichiometry of the PF-fluoride
complex is 1:1. The formation of the fluoride complex is essentially irreversible as the
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absorptions corresonding to the starting PF could not be observed even after addition of
one mol equivalent ofTBAF. The ortho- fluorines are relatively more shielded in the PFfluoride complex (28) as compared to the meta- and para-fluorines, as expected due to
the proximity of the negatively charged boron.
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Figure 4.16. 19F NMR (376MHz) spectra ofDF (23), TF (24), and PF (25) in
acetonitrile at various molar equivalents ofTBAF: boroxin: TBAF = 1:3 (A); boroxin:
TBAF = 1:2 (B); boroxin : TBAF = 1: 1 (C); boroxin without added TBAF (D).
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11

4.3.5

B NMR Studies and GIAO Calculations. The

11

B NMR for the

fluoride complexes (26, 27, and 28) are shown in Figure 4.17. DF-fluoride complex (26)
shows two

11

11

2

3

B absorptions at 8 B 19.8 (sp "B) and 1.2 (sp "B). TF-fluoride complex

and PF-fluoride complexes similarly show two

11

B absorptions: 8 11 B (TF): 20.1 (sp2"B)

and 1.2 (sp3·B); 8 11 B (PF): 20.4 (sp2 B) and 1.2 (sp3B). The DFT-GIAO derived
chemical shifts are in reasonably close agreement (L.\8 = 2.8 to 5.9) with experimental
values so that the assignments of the

11

B absorptions in the complexes could be

confirmed.
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Figure 4.17. 11 B NMR (128 MHz) spectra ofDF (23), TF (24), and PF (25) in
acetonitrile at various molar equivalents ofTBAF: boroxin : TBAF = 1:3 (A); boroxin :
TBAF = 1:2 (B); boroxin : TBAF = 1: 1 (C); boroxin without added TBAF (D).
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In the presence of I mol equivalent ofTBAF, about 20% of the unreacted stat1ing
11

materials could be observed in case ofDF and TF, in addition to the above two B
absorptions for the fluoride complexes, 26 and 27, showing their equilibration with
residual boroxines. Further, the chemical shifts of the sp3·hybridized boron in complexes
26 and 27 is shielded by 2 ppm in the presence of two equivalents ofTBAF, presumably
due to the weak binding of the second fluoride anion to these complexes.
Addition of l mol equivalent ofTBAF to PF, however, resulted in instantaneous
complete disappearance of the slatting material as monitored by 11 B NMR spectroscopy.
The PF-fluoride complex, 28, showed three relatively broad signals at o11 B 20.4 (sp2 B),
2.2 (sp3 B),l.4 (sp 3 B) (Figure 4.15). Further addition ofTBAF to this solution resulted
gradual broadening of the peak at 2.2 ppm. Although we cannot clearly rationalize this
unexpected observation for PF, perhaps a second fluoride anion binding may be involved
in this case. In accordance with this expectation, UV -vis studies also show possible
existence of multiple equilibria, i.e., co-existence of more than one PF-fluoride complex
(vide inji-a). Upon further addition of up to 3 mol equivalents ofTBAF the spectra for

boroxin-fluoride complexes, 26, 27, and 28 remained unchanged.

4.3.6

UV-Vis Studies. UV-vis spectroscopy is commonly used to identify the

stoichiometry of host-guest complexes.llSJ In order to futther confirm the

19

F NMR

derived stoichiometry for the boroxin-fluoride complexes, we have carried out UV-vis
studies for these complexes using continuous variation method (Job's plots).
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UV-Vis spectra were recorded for a series of DF/TBAF (PF/TBAF) solutions; the
mol ratios of DF to fluoride (PF to fluoride) were continually varied while keeping the
total concentration of each of their solutions constant. The measured UV -vis absorbances
at 265, 265, 260, and 64 nm (multiplied by mol fraction of boroxines) were plotted
against mol fractions of the TBAF (Figure 4.18). 136•371 Through these Job 's plots,
stoichiometry of the DF-fluoride complex was determined as 1: 1. In case of DF 1: 1
stoichiometry is consistently observed at all wavelengths: 269, 265, 260, and 64 nm
(Figure 4.18B) Stoichiometry of host-guest complexation is independent of UV -vis
wavelength in Job's plots, if a single complex is formed. On the other hand, dependence
of Job's maxima on wavelength is indicative of the co-existence of more than one
complex.l3SJ,[38 .391 The Job's plots for PF, show deviations from 1:1 stoichiometry at
different wavelengths, indicating the possible co-existence of more than one complex for
PF (Figure 4.18C) (vide supra) .

....

~

OOOG

11 11!'1

"~
II \ ~

~

Il l

t "H
111

1<Ill <
Il l

....

~

0~

~L
:..&•1

-

1•• -• llt.\1

- IIK H II C.\1

- 111Jo7 llllr
- ll <n•tllt\1
- IIHliH\1'
II ll{oi iH.\1
- llll •tl ll.\ 1
l 'JI I

i ,l ,':-· ·:\ \
::::1

41 ,; ·

•

u u 111 211 lu ~~~ ~~~ , , u .,.u :OC.II 'I 1

1i·~

....

:.· ~~1111

: D:>~ :·,:.:.
0 001
0

: .:

/:

f.···
0

/

...

\

· • · IGOnnl
· • · 2!.4nrn
16~nm

• · · 26?nm

.

.\.

0 1 02030< 0 ~0.~0.1 0.809

•
I

Mlfl

\\ a,,h·n ~lh(nm)

A

•
·•

/ ..'.\

B

c

Figure 4.18. UV-Vis Spectra (in acetonitrile) obtained from continuous
variation method (A), and Job' s plots for DF(B) and PF(C); B and Care the overlay
plots for absorbances at 269, 265, 260 and 65 nm.

149

4.3.7 Ab initio Structures of Boroxin-Fiuoride Complexes. We have
optimized structures of symmetrically bound and unsymmetrically bound fluoride anion
complexes of DF at B3L YP/6-31 G** level in order to clarify the nature of the fluoride
anion binding to the cyclic boroxines. Aldridge and coworkers have earlier shown that a
related tribora-macrocyclic compound, I ,4, 7 -trifloro-1 ,4, 7-triboracyclononane (30)
( Figure 4.19) and its perfluorinated analog have symmetrical fluoride anion binding to
all three boron atoms, at HF16-31 +G* level. [401

RylrR
FYF

R~~~;~~R

RYF FYR
R

R

30

R~H!F

29
Figure 4.19. Structures of fluorinated boroxin and 1,4,7-trifloro-1,4,7triboracyclononane showing symmetircal fluoride binding.

However, we have found at higher DFT levels of calculations at B3L YP/6311 G** that the symmetyrical C3v structure for the complex, 29, is relatively 12.5
kcal/mol higher in energy as compared to that of the unsymmetrically bound species, 26.
Structures 26 and 29 are energy minima on the potential energy surface at this level of
theory (Figure 4.20). The relatively low energy for the unsymmetric structure (26)
implies its entropic advantage over the symmetric structure, 29. The fluoride bound

ISO

complex, 26, shows significantly upfield shifted

19

F signals for the fluorine atoms

attached to aromatic rings. However, we were not able to observe the absorptions
corresponding to the fluoride anion attached to boron.

Figure 4.20. 831YP/6-311 G** structures of asymmetic and symmetrically
bridged [DF-Fr complexes, corresonding to structures 26 (left) and 29 (right).

The lack of detection of the boron-bound fluoride absorption indicates that there
is rapid equilibrium between three unsymmetrical structures relative to the NMR time
scale at ambient temperature with an estimated free energy of activation of 12.0 to 12.5
kcal/mol (vide supra). Geometries for the PF and [PF-Fr are shown in (Figure 4.21). In
the neutral form the PF anion receptor is a propeller shape molecule with a small angle
(36.4 degrees) between the boroxin ring and the phenyl groups. In the charged state [PFFr the boron atom that captures the fluoride anion becomes more tetragonal and the
propeller angle increases significantly (79.7 degrees).
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Figure 4.21. B3L YP/6-311 G** solution (propylene carbonate) geometry-optimized
structures of neutral PF (left) and the corresponding charged [PF-Fr complex (right).

4.3.8

Tandem Mass spectroscopic Studies of Boroxin Fluoride Complex. In

light of the importance of the selective binding of the electrolyte materials to the anion
receptors, it is useful to characterize the structural detai Is of the boroxin-anion
complexes. Electrospray ionization mass spectroscopy in the negative ion mode is ideally
4142

suited for characterization ofthe stoichiometry of the fluoride anion complexes.[

J

Competitive ESI-MS studies also would provide quantitative information on the relative
bidning affinities. Further, the tandem mass spectrometric fragmentations would reveal
the mechanistic aspects of the rearrangements involved in the fragmentations. We now
report the electrospray mass spectrometric characterization of the molecular ion
complexes for these fluorinated boroxines, also substantiated by the DFT studies.
Electrospray ionization mass spectroscopy (ESI-MS) is expected to show the molecular
ion peaks for the boroxin anion complexes, and thus direct characterization of the anion

!52
complexes could be achieved. The molecular ion peaks for the fluoride anion adducts for
DF, TF, and PF, corresponding to m/z of 439, 493 and 601, respectively were observed.
The observed isotopic ratios for MF-2, MF-1, MF, and MF+ 1 for DF-F", TF-F, and PF-F"
are generally in accordance with the calculated ratios, confirming these peaks as the
molecular ion peaks for the fluoride adducts( Figure 4.22).
Tandem mass spectrometry is useful in the characterization of the fragmentation
mechanisms. The fragmentation mass spectrum obtained by the collision induced
dissociation (CID) of the DF-fluoride (26) molecular ion peak at 439 showed appearance
of the peaks at m/z 345, 61, 113 (Figure 4.23). These m/z values could be readily
assigned to the anion species 26a, 26b, and 26c arising from the successive eliminations
of3.f1uorobenzyne and 1,3,5-trifluoroboroxin, as shown in (Scheme 4.11). Similar
fragmentation pattern was observed in case of other boroxines fluoride complexes, TF-F
and PF- F.
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Figure 4.22. Electron spray ionization mass spectrum (EST/MS) of DF-Fluoride
complex showing isotopic pattern.
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Figure 4.23 . ESIIMS spectra showing the molecular ion peaks for the boroxin-fluoride
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4.3.9

Theoretical Studies: 1,3-sigmatropic Rearrangement. The

fragmentation pattem of the ESI-MS/MS of the DF, TF, and PF fluoride anion complexes
show the involvement of a 1,3 .sigmatropic migration of the orlho-fluorine from the aryl
rings to boron in concert with elimination of fluorobenzyne (Scheme 4.1 0). Such
1,3.fluoride migrations to boron have not been reported to date to the best of our
knowledge, although several such shifts have been observed for the allyl fluorides. [43 -45 1
The 1,3.sigmatropic fluorine sifts to silicon have also been reported in the 2.phoshspha1,3.disilallyl fluoride derivative.[461 Recent DFT theoretical studies indicate that this
allowed suprafacial rearrangement proceeds with a four membered C, transition state in
which migrating fluorine has a charge of -0.6e.[471 The 1,3.sigmatropic fluorine
migrations to boron have never been reported to the best of our knowledge. In order to
probe the nature of the 1,3.sigmatropic shift of fluoride to boron we have calculated the
transition structures for these sigmatropic shifts for [DF-Fr anion complexes using
structures 31 as a small molecule model compound. We have also carried out similar
calculations on the negatively charged model compound 31, in order to see if fluoride
migrations can take place to the sp3·B center.
The calculated transition structures (Figure 4.24) have a single negative eigen
value and the negative imaginary frequency corresponded to the migrating fluorine
bonds, as shown by theIR spectral animations. The activation barriers for the 1,3.shift of
fluorine for compounds 31 and 32 at B3L YP/6-311 G** were found to be 32.3 and 56.2
kcal/mol, respectively (equations 3 and 4).
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Thus expectedly, the 1,3.shift of fluorine to the electrophilic sp2 'B (in compound
31) is relatively much faster than that of the sp3·B center (in compound 32). In
accordance with these DFT computations, the fragment ion 26b gave anion 26c by the
cleavage of the boron-aryl bond, and the corresponding 1,3-sigmatropic fluorine
migration was not observed(Scheme 4.11 ).

Figure 4-24. Transition state for fluoride migration (II)
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4.3.10 Competition Binding Studies of Boroxin- Fluoride Complexes. Earlier
DFT computations show that as the number of fluorine atom on the aryl rings of
boroxines increase their binding efficiency increases. [4SJ The isodesmic reactions for the
competitive binding of fluoride to DF, TF, and PF, at B3L YP/6-311 G**, show that the
PF-fluoride complex is more stable than DF-fluoride and TF-fluoride complexes by 6.6
kcal/mol, and 4.8 kcal/mol, respectively, implying insignificant amounts of DF-fluoride
and TF-fluoride complexes (0.0014% and 0.029%, respectively) in an equilibrium
mixture of all these three boroxines in the presence of fluoride anion (equations 5 and 6).

PF

Expected ratio: PF-Fr
PF

PF-Fr + DF

+ DF-Fr

DF-F]"

+ TF-F]"

99.998
PF-Fr + TF

flG*

=

-6.6 kcaV1nol

0.0014
6.G*

=

(5)

-4.8 kcallmol
(6)

Expected ratio: PF-Fr

TF-F]"

99.97

0.029

Indeed, when an equimolar mixture ofDF, TF, PF in the presence of of0.33 mol
equivalent TBAF was subjected to ESI mass spectrometric analysis, the appearance of
exclusively PF-fluoride complex at m/z 601( Figure 4.25) was found. The mass peaks
due to the DF-floride and TF-fluoride complexes were observed under these conditions,
which is in accordance with these calculations.
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Figure 4.25. ESI/MS spectrum ofequimolar mixture ofDF, TF and PF in the presence
of 0.33 equivalents ofTBAF.

Lithium hexafluorophosphate is commonly added as supporting electrolyte in the
lithium ion batteries, and therefore it is interesting to compare its relative binding
efficiency with anion receptors. It would be also informative to compare the fluoride
anion binding strength with that of other commonly used halide anions.
Thus, we have extended these anion binding studies to other halide anions
(chloride, bromide, and iodide anions), and hexafluorophosphate. When each of these
boroxines was separately mixed with TBACl, TBABr, TBAI, and TBAPF6 and
subjected to negative ion ESI mass spectrometry, we have not been able to observe the
corresponding molecular ion peaks for the anion adducts( equation 7, 8 and 9, (No
detectable MX]- peaks) in ESI-MS ).
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BuN +x OF

~

~

o r-xr

(7)

TF - x r

(8)

X = Cr,Br-,PF 6 BuN +xTF

"
"

X = Cr, Br-, PF 6 -

(9)

BuN +x PF

r r-xr

X = cr, Br -, PF 6 -

The ESI mass spectrum of an equimolar mixture of the OF, TBACl, TBABr,
TBAI, TBAF, on the other hand, showed exclusively the molecular ion peak for the DF-F
anion complex (Figure 426) _ These results imply the extremely weak binding affinities
of chloride, bromide, iodide, and hexafluoroposphate anions to the boroxines.

Figure 4.26. ESI/MS spectrum of an equimolar mixture of OF , TBACl, TBABr,
TBAI, TBAF.
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4.3.11 NMR Studies of Anion Binding.

19

F NMR titration ofDF with

tetrabutyl ammonium salts of anions such as tetrabutylammonium chloride (TBACl),
tetrabutyl ammonium bromide (TBABr), tetrabutylammonium iodide(TBAI), and
tetrabutylammonium phosphate (TBAPF 6) resulted in no upfield shift of peaks due to
anion binding even at DF: anion ratio of 1:2 , indicating that there is either no binding or
week binding. The relatively small downfield shift may be due to salt effect (Figure
4.27).ln summary, fluorinated arylboroxines are efficient anion receptors, comparable to
the state-of- the-att PFPB anion receptor. 124 ' 25 · 331 The structures of the fluoride complexes
11

DF, TF, and PF are confirmed by matching the experimental 19F and B NMR chemical
shifts with those obtained from DFT calculations. Further EIIMS studies confirmed the
structure of these boroxines.Our Ab-initio calculations show that the symmetrically
bound fluoride complex, 29, is, unexpectedly, less favorable as compared to the
unsylllllletrically bound species, 26, by 12.5 kcal/mol. The coalescence of the 19 F NMR
signals of these boroxines at ambient temperature shows relatively rapid equilibration of
the fluoride anion among the three boron atoms in these boroxines, with an estimated
upper limit of about 12 kcal/mol.
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Figure 4.27. 19F (376 MHz) NMR spectra of DF in dichloromethane in the presence of2
equivalents of tetrabutyl ammonium salts of anions, TBAF, TBACl, TBABr, TBAI,
and TBAPF6.

Our electrospray mass spectroscopic studies in combination with ab intio
DFT theory show that the fluorinated boroxines are highly selective to fluoride anion
binding, and their relative binding to other halide anions and hexafluorophosphate is
insignificant. Using tandem ESI mass spectroscopy we have characterized the
fragmentation patterns for the fluorinated boroxin-fluoride anion complexes and
identified the first 1,3 .sigmatropic shift of fluorine to boron. The activation barriers for
the 1,3 .fluoride anion migration to boron has been estimated as 32.3 kcal/mol at
B3L YP/6-311 G**.

161

4.4

EXPERIMENTAL SECTION
4.4.1

Materials. Acetonitrile (anhydrous, >99.8%), dimethylsulfoxide

(>99.6%, dichloromethane (>99.8%), ethyl acetate (>99.5%), and tetrabutylammonium
fluoride hydrate (>98%) were obtained from Aldrich and used as received. The
fluorinated boroxines DF (23), TF (24), and PF (25) were obtained by thermal
dehydration of the corresponding arylboronic acids, at 100 °C for about one hour.l271The
products were obtained essentially pure as confirmed by their 19F NMR and 11 B NMR
spectra (vide infi'a). Further confirmation of the structures were provided by matching the
observed chemical shifts with those obtained at GIAO/B3LYP/6-31G** level.[JOJ

4.4.2

NMR Spectra.

19

F NMR spectra (at 376 MHz) and

11

B NMR spectra

(128Hz) were obtained on a Varian !nova 400 MHz spectrometer in anhydrous CH3CN
(in unlocked mode) or CD 3CN solutions.
0), and

11

19

F NMR spectra referenced to CFCh (8 19 F =

B NMR spectra are referenced to BF3.0Et2 (8 11 B = 0). All the NMR spectra

were processed using MestReNova 6.2.0 software.
A series of solutions (about 200 mM) of boroxines (DF, TF, and PF) were
prepared by dissolving each of the boroxines in various solvents (acetonitrile, DMSO,
ethyl acetate, and dichloromethane), and appropriate amounts of tetrabutylammonium
fluoride (TBAF) was added to them so that the resulting solutions had mol ratios of
boroxin:fluoride as 1:0, 1:1, 1:2 and 1:3. These homogenous solutions were transferred
into 5 mm NMR tubes, CFCh was added as an internal reference, and
were recorded at ambient temperature.

11

19

F NMR spectra

B NMR spectra were obtained for the same

solutions using BF3.etherate as external reference.
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The reaction of boroxines (DF, TF, and PF) with fluoride anion was exothermic.
A clear homogeneous solutions resulted immediately after the addition of TBAF to DF
and TF.

However, reaction of PF with TBAF gave homogeneous solutions only in

DMSO, acetonitrile and dichloromethane, but not in ethyl acetate. The 11 B and

19

F NMR

spectra for the boroxines and their fluoride complexes 26, 27, and 28 (I: I mol ratio) in
acetontrile are as follows:
DF: 1i 19F -103.0 (broads); 1i 11 B 28.5.
TF: 1i 19 F -99.9 (apparent triplet, J

=

7.5 Hz, ortho-F), 106.8 (t, J

=

8 Hz; para-F);

1i 11 B 28.0.
PF: 1i 19F -132.4 (m, ortho-F), -153.7 (t, J

=

19Hz, para-F), -163.5 (m, meta-F). 1i 11 B

27.3 (broads), 20.4 (broads).
Complex 26: 1i 19F -110.4 (broads, ortho-F); (additional small peaks, 1i 19 F -102 to -105,
were observed, presumably corresponding to multiple fluoride exchange equilibria).;

1i 11 B 28.5(broad s), 20.4(broad s), 3.0(m).
Complex 27: 8 19 -107.9 (m, ortho- and para-F) (additional small peaks, 1i 19F -98 to -115,
were observed, presumably corresponding to multiple fluoride exchange
11

equilibria); 1i B 28.0(broad s), 20.l(broad s), 2.8(m).
Complex 28: PF: 1i 19 F -139.3 (m, ortho-F), -155.3 (!,para-F), -162.9 (m, meta-F). 1i 11 B
20.4(broad s), 1.95 (broads), 1.2 (m).
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Addition of2 mol equivalents ofTBAF simplified the

19

F NMR spectra of the

complexes 7 and 8. There was no apparent change in the spectra of complex 9. The o19 F
remained constant upon fmiher addition of up to 3 mol equivalents ofTBAF to each of
these complexes (7, 8, and 9). The

19

F and 11 B NMR spectra of these complexes with two

mol equivalents offlum·ide anion are as follows:

Complex 26 (with excess TBAF):

o19F -110.4 (broads); o11 B 20.4 (broads),

1.2 (broads).

Complex 27 (with excess TBAF):

o19F -107.9 (m, ortho- and para-F); o11 B

Complex 28 (with excess TBAF):

o19F

Hz, para-F), -162.9 (m, meta-F);

o11 B 20.4 (broads), 1.2 (broads).

4.4.3

PF:

o19F

20.4, 1.2.

-139.3 (m, ortho-F), -155.3 (t, J = 19

UV-Vis Spectroscopic Studies. UV-Vis spectroscopic studies were

carried out on a Cary-50 UV -vis spectrophotometer equipped with a !.em path-length
quartz cell by monitoring the absorbances between 200 to 300 nm. The micropipettes
used were capable of delivering I mL solutions, having adjustable ranges between I 00
11L- I 000 J.lL. All UV-Vis measurements were performed at ambient temperature. I x
10-5 M Stock solutions of DF (23), PF (25), and tetrabutylammonium fluoride (TBAF)
were prepared in acetonitrile. Stoichiometry of the DF-fluoride (PF-fluoride) complexes
was determined using Job's continuous variation method as follows:
A series of solutions consisting of DF (PF) and TBAF were prepared by mixing
the above stock solutions so that the total concentration of the combined solutions was
maintained constant at I x I o- 5 M, and the UV absorbances were recorded separately for
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each solution. Stoichiometry of the complexes was dete1mined by a plot of the
absorbances (multiplied by mol fraction ofboroxines) versus mol fractions of the TBAF.

4.4.4

Ab- Initio Calculations. We conducted thermodynamic calculations, in

the form of electronic energies, solvation free energies in propylene carbonate, and
49
binding energetics using Quantum Mechanical Density Functional Theory (B3L YPi 1
for reactions of fluoride anion binding to novel fluorinated phenyl boroxin anion
receptors. We performed full geometry optimizations with solvation effects obtained
through a continuum dielectric model. [SOJ The molecular solvation surface of the anion
receptor was defined with the molecular radius (2. 7A) and dielectric constant of
propylene carbonate (c=64.5). All wave functions are open shell (UDFT), calculated
with a high level basis set (LACVP**) which translates to 6-311 G** basis for main
group elements. Ab-initio calculations were carried out on a Dell Linux Cluster (80
node/160 core, Single Core Xeon, 3.06GHz) running Linux/OSCAR, with 160GB of
RAM, and 8.6TB of disk space. 11 B and 19F NMR chemical shifts were calculated using
density functional theory, at B3LYP/6-311G** level) for the various fluorinated
receptors and fluoride complexed anions. The geometries were fully optimized (basis set
6-311 G**) in a continuum dielectric medium appropriate for propylene carbonate (PC).
The 19 F and 11 B NMR chemical shifts are computed with respect to CFCb (o 19 F = 0.0)
and BF 4. (o 11 B

=

0.0), respectively. The latter o11 B (BF 4.) are re-converted to

o11 B(Bf]Et20). (o 11 B(BF4.) = -2.2 with respect to o11 B (BfJ,OEt2 ; o11 B = 0).

165

4.4.5

Mass Spectroscopic Studies.

EVMS spectra were obtained on Hewlett

Packard 59892A Mass spectrometer. The HP 59882A direct insertion probe provided the
way to introduce solid in to the EI ion source. Approximately 1mg of the sample was
placed in a piece of glass capillary tubing and is loaded in to the tip of the probe. The
probe was insetted in to the MS engine ion source. EI/MS spectra were recorded at 70eV.
The oven temperature was ramped from 50 °C to 280 °C at 20 °C/min and then heated for
5 minutes at 280 °C.ESI/ MS/MS studies were carried out on a Varian 1200L Quadrupole
MS/MS spectrometer. All the experiments were done in negative ion detection scan mode
(m/z = 50 to 600). Needle voltage of -4500 Volts, drying gas temperature of 50 °C to
100 °C, and a flow rate was 50 ~.tLimin were used. Nitrogen was used as the nebulizing
gas.The parent molecular ion (M') in ESI/MS was used for Tandem MS analysis. The
instrumentation conditions are as follows: negative ion detection, scan mode,· needle
voltage = 4500, detector voltage = 1600 Volts, syringe solvent flow rate = 50

~.tLimin,

nebulizing gas = nitrogen, collision gas = argon. The drying gas temperature was varied
between 50 °C and l 00 °C for optimal conditions; The ESI-MS molecular ion peaks for
the DF, TF, and PF fluoride complexes are as follows: DF-Fluoride complex (MF), m/z
= 439; MF-2:MF-1:MF: MF+1 = 43:88:100:21 (calculated ratio 16:68:100:19); TFFluoride complex (MF'), m/z= 493, MF-2:MF-l:MF:MF+l = 32:98:100:21 (calculated
ratio 16:68:100:19); PF-Fluoride complex (MF'), mlz= 601, MF-2:MF-1:MF:MF+1 =
38:98:100:35 (calculated ratio 16:68:100:19). The CID-MS/MS of the DF-Fluoride ion
complex at m/z 439 showed peaks at m/z 345, 61 and 113; The CID-MS of the TFFluoride ion complex at m/z 493 showed peaks at m/z 369,281 and 131; The CID-MS of
the PF-Fluoride ion complex at m/z 601 showed peaks at m/z 453, 305 and 167.
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